zalcitabine has been researched along with didanosine in 386 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (0.78) | 18.7374 |
| 1990's | 308 (79.79) | 18.2507 |
| 2000's | 52 (13.47) | 29.6817 |
| 2010's | 21 (5.44) | 24.3611 |
| 2020's | 2 (0.52) | 2.80 |
| Authors | Studies |
|---|---|
| Aoki, S; Barchi, JJ; Driscoll, JS; Ford, H; Kelley, JA; Marquez, VE; Mitsuya, H; Shirasaka, T | 1 |
| Antonenko, SV; Chentsova, NP; Kukhar, VP; Luik, AI; Poda, GI; Tetko, IV | 1 |
| Gam, J; Kim, DK; Kim, HT; Kim, KH; Kim, YW; Lim, J | 1 |
| Cha, SH; Endou, H; Kanai, Y; Kimura, M; Sekine, T; Tsuda, M; Wada, S | 1 |
| Bader, JP; Cragg, GM; Newman, DJ; Yang, SS | 1 |
| Alam, N; Hong, J; Im, KS; Jung, JH; Lee, CK; Li, F; Liu, Y; Wang, W | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lund, KC; Peterson, LL; Wallace, KB | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E | 1 |
| Amblard, F; Bassit, L; Bondada, L; Coats, SJ; Detorio, M; Grier, J; Hernandez-Santiago, BI; Koontz, D; Mellors, JW; Rapp, KL; Schinazi, RF; Sluis-Cremer, N | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Kang, JA; Kim, WH; Lee, CK; Lee, HJ; Moon, HR; Park, AY | 1 |
| Chen, W; Chen, X; De Clercq, E; Li, D; Li, X; Liu, X; Pannecouque, C; Tian, Y; Zhan, P | 1 |
| Achary, R; Han, SB; Jeong, HC; Jung, YS; Kim, JN; Kim, M; Kim, P; Kim, SY; Lee, CK; Malpani, Y | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Balzarini, J; Chen, FE; Chen, WX; Daelemans, D; De Clercq, E; He, QQ; Pannecouque, C; Wu, HQ; Yan, ZH | 1 |
| Arumugam, SR; Badri, KR; He, JJ; Visalli, RJ; Zhang, X; Zhao, H; Ziobrowski, H | 1 |
| Bingöl Özakpınar, Ö; De Clercq, E; Küçükgüzel, İ; Kulabaş, N; Özsavcı, D; Pannecouque, C; Tatar, E | 1 |
| Buckheit, RW; Cushman, M; Hartman, TL; Hoshi, A; Okazaki, M; Pannecouque, C; Sakamoto, T; Takayama, J; Xuan, M | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Gao, Q; Gu, Z; Li, X; Parniak, MA; Wainberg, MA | 1 |
| Fauci, AS | 1 |
| Caliò, R; Perno, CF | 1 |
| Brett, CM; Giacomini, KM; Hui, AC; Wu, X; Yuan, G | 1 |
| Johnson, VA | 1 |
| Kahn, J | 1 |
| Balzarini, J; Bergamini, A; Calio, R; De Clercq, E; Milanese, G; Pauwels, R; Perno, CF; Rocchi, G; Yarchoan, R | 1 |
| Husson, RN; Pizzo, PA | 1 |
| Hammer, SM; McLeod, GX | 2 |
| Saag, MS | 2 |
| Skowron, G | 1 |
| Watson, AJ; Wilburn, LM | 1 |
| Garfunkel, AA; Glick, M | 1 |
| Boon, GD; Chan, TC; Redmond, R; Shaffer, L | 1 |
| Bawdon, RE; Dax, J; Sobhi, S | 1 |
| Chattopadhyaya, J; Koole, LH; Plavec, J | 1 |
| Foerster, M; Kastner, U; Neubert, R | 1 |
| Lane, HC | 1 |
| Cooper, DA; Danner, SA; Lange, JM | 1 |
| Broder, S; Caliò, R; Cooney, DA; Foli, A; Gao, WY; Hao, Z; Hartman, NR; Johns, DG; Perno, CF; Yarchoan, R | 1 |
| Cameron, JM; Cammack, N; Coates, JA; Jenkinson, HJ; Jowett, AJ; Jowett, MI; Pearson, BA; Penn, CR; Rouse, PL; Viner, KC | 1 |
| Keilbaugh, SA; Prusoff, WH; Simpson, MV | 1 |
| Rousseau, F; Sereni, D | 1 |
| Goldsmith, MF | 1 |
| Fischl, MA | 1 |
| Anastasi, JK; Rivera, JL | 1 |
| Alkan, M | 1 |
| Butler, K; Husson, R; Marshall, D; Pizzo, PA; Roilides, E; Venzon, D | 1 |
| Ayisi, NK; Gupta, SV; Qualtiere, LF | 1 |
| Cao, W; Fuchs, BA; Germolec, DR; Luster, MI; Munson, AE; Prejean, JD; Rosenthal, GJ; Shopp, G; Thompson, MB; Tomaszewski, JE | 1 |
| Pinching, AJ | 2 |
| Gallo, JM; Qian, MX; Swagler, AR | 1 |
| Hirsch, MS | 1 |
| Horgan, J | 1 |
| Broder, S; Kageyama, S; Mitsuya, H; Yarchoan, R | 1 |
| Broder, S; Mitsuya, H; Perno, CF; Pluda, JM; Yarchoan, R | 1 |
| Mitsuya, H | 2 |
| Fernández-Cruz, E | 1 |
| Cersosimo, RJ; Matthews, SJ; Spivack, ML | 1 |
| Schaefer, E | 1 |
| LeLacheur, SF; Simon, GL | 1 |
| Merigan, TC | 1 |
| Burke, A; Martin, JA; Mobberley, MA; Redshaw, S; Ryder, TA; Tyms, AS | 1 |
| Chen, CH; Cheng, YC; Vazquez-Padua, M | 1 |
| Foth, H; Frijus-Plessen, N; Kahl, GF; Michaelis, HC | 1 |
| Cotton, P | 1 |
| Hoth, D | 1 |
| Pizzo, PA; Roilides, E; Rubin, M; Venzon, D | 1 |
| de Noronha, F; Postie, L; Roneker, C; Tavares, L | 1 |
| Hill, DL; Kalin, JR | 1 |
| González-Lahoz, J; Soriano, V | 1 |
| Portegies, P | 1 |
| Cauda, R; Donelli, G; Landay, AL; Lucia, MB; Malorni, W; Ortona, L | 1 |
| Ali, SF; Binienda, Z; Lipe, G; Parker, WB; Rose, LM; Sandberg, JA; Slikker, W | 1 |
| Carr, A; Cooper, DA; Loewenthal, M | 1 |
| Mitsuya, H; Shirasaka, T | 1 |
| Balfour, HH; Erice, A | 1 |
| Cameron, J; Fang, H; Gao, Q; Goldberg, E; Gu, Z; Parniak, MA; Salomon, H; Wainberg, MA | 1 |
| Connell, EV; Hsu, MC; Richman, DD | 1 |
| Baba, M; Ikeuchi, T; Korenaga, H; Osada, Y; Shigeta, S | 1 |
| Caliendo, AM; Hirsch, MS | 1 |
| Britton, S; Julander, I | 1 |
| Arts, EJ; Fletcher, RS; Gu, Z; Parniak, MA; Wainberg, MA | 1 |
| Brennan, TM; Bridges, CG; Leyda, JP; Taylor, DL; Tyms, AS | 1 |
| Clifford, DB; Fichtenbaum, CJ; Powderly, WG | 1 |
| Barry, DW; Pennington, KN; Rooney, J; St Clair, MH | 1 |
| Abrams, D; DeMets, DL; Fleming, TR; Goldman, A; Korvick, J; Launer, C; Neaton, JD | 1 |
| Farr, SS; Kammerman, LA; Kazempour, K | 1 |
| Stephenson, J | 1 |
| Choo, V | 1 |
| Dillner, L | 1 |
| Dalakas, MC; Lewis, W | 1 |
| Stretcher, BN | 1 |
| Domanski, MJ; Egan, D; Follmann, DA; Pizzo, PA; Scalise, PP; Sloas, MM; Tucker, EE | 1 |
| Gunnarsson, G; Hammer, SM | 1 |
| Hoernle, EH; Reid, TE | 1 |
| Chokekuchai, S; Gao, WY; Johns, DG; Mitsuya, H | 1 |
| Kamali, F | 1 |
| Anderson, BD; Kojima, E; Mitsuya, H; Shirasaka, T; Yarchoan, R | 1 |
| Baseler, MW; Foli, A; Saville, MW; Yarchoan, R | 1 |
| Lissen, E | 1 |
| Simpson, DM; Tagliati, M | 1 |
| Khoo, SH; Wilkins, EG | 1 |
| Agbaria, R; Cooney, DA; Fornace, AJ; Johns, DG; Sreenath, A; Stowe, EE; Zhan, Q; Zhang, H | 1 |
| Brivet, FG; Dormont, J; Lemaigre, GF; Naveau, SH | 1 |
| Dall, L; Tal, A | 1 |
| Back, DJ; Barry, MG; Veal, GJ; Wild, MJ | 1 |
| Krasinski, K | 1 |
| Spector, SA | 1 |
| Abrams, DI | 1 |
| Dormont, J | 1 |
| Dudley, MN | 1 |
| Carpenter, CC; Cobbs, CG; Holmes, KK; Sande, MA; Sanford, JP | 1 |
| Houston, SC; Ostashewski, PM; Robertson, JA | 1 |
| Klein, HG; Kumar, P; Merritt, S; Sacher, R; Sloand, E | 1 |
| Lancaster, DJ; Lancaster, LL | 1 |
| Abrams, DI; Crane, LR; Goldman, AI; Grodesky, M; Kornegay, S; Korvick, JA; Launer, C; Muth, K; Neaton, JD; Wakefield, S | 1 |
| Grange, JM; Hamedi-Sangsari, F; Malley, SD; Vila, JR | 2 |
| Stretcher, B | 1 |
| Picard, O | 1 |
| Craib, KJ; Hogg, RS; Montaner, JS; O'Shaughnessy, MV; Schechter, MT; Strathdee, SA | 1 |
| Hirschel, B | 1 |
| Gao, WY; Johns, DG; Mitsuya, H | 1 |
| Cheng, YC; Hsiung, GD; Medina, DJ; Tsai, CH | 1 |
| Lüthy, R | 1 |
| Gao, Q; Gu, Z; Nagai, K; Parniak, MA; Salomon, H; Wainberg, MA | 1 |
| Morris, DJ | 1 |
| Portet-Brunet, L | 1 |
| Gobert, JM; North, TW; Remington, KM; Zhu, YQ | 1 |
| Bincsik, A; Lane, J; Mayers, D; Otto, MJ; Scarnati, H; Winslow, DL | 1 |
| Volberding, PD | 1 |
| Lipsky, JJ | 1 |
| Bergé, P; Mildvan, D; Salgo, M; St Clair, M; Starrett, S | 1 |
| Volberding, PA | 1 |
| Magnuson, T; Mourton, T; Toltzis, P | 1 |
| Dalakas, MC; Jay, C; Ropka, M | 1 |
| Cinatl, J; Doerr, HW; Kornhuber, B; Mainke, M; Rabenau, H; Weber, B; Weissflog, A | 1 |
| Arduino, JM; Chung, R; Crumpacker, CS; Hammer, SM; Japour, AJ; Lane, J; Mayers, DL; McLeod, GX; Reichman, R; Wagner, KF | 1 |
| Armbrecht, C; Hengels, KJ; Jablonowski, H; Manegold, C; Mauss, S; Szelenyi, H | 1 |
| Dubin, DT; Farnham, AE; Fitzgibbon, JE; Kim, H; Sperber, SJ | 1 |
| Chow, FP; Hamburger, AW; Ordóñez, JV; Sutton, PA | 1 |
| Mayaud, C | 1 |
| Brun-Vezinet, F; Pépin, JM; Simon, F | 1 |
| Anderson, BD; Broder, S; Husson, RN; Kojima, E; Mitsuya, H; O'Brien, MC; Shimada, T; Shirasaka, T; Yarchoan, R | 1 |
| Lang, W; Moss, A; Osmond, D; Page-Bodkin, K; Winkelstein, W | 1 |
| Bucher, GG | 1 |
| Broder, S; Gao, WY; Johns, DG; Mitsuya, H; Shirasaka, T | 1 |
| D'Aquila, RT; Hirsch, MS | 1 |
| Ratner, L; Vander Heyden, N | 1 |
| Butler, KM; Husson, RN; Mitsuya, H; Pizzo, PA; Shirasaka, T | 1 |
| Boucher, C; Cameron, J; Cammack, N; Gao, Q; Gu, Z; Parniak, MA; Wainberg, MA | 1 |
| Brawley, O; Broder, S; Cohen, RB; Nguyen, BY; Pluda, JM; Shay, LE; Venzon, DJ; Whitcup, SM; Wyvill, KM; Yarchoan, R | 1 |
| Clumeck, N | 1 |
| Chien, YW; Kim, DD | 2 |
| Cooper, DA; Emery, S | 1 |
| Arts, EJ; Gu, Z; Le Grice, SF; Marois, JP; Wainberg, MA | 1 |
| Gerstoft, J; Pedersen, BK | 1 |
| Abrams, DI; Carlin, BP; Crane, LR; Deyton, L; Goldman, AI; Korvick, JA; Launer, C | 1 |
| Brenner, B; Lalonde, R; Mercure, L; Phaneuf, D; Wainberg, MA | 1 |
| Barbosa, P; Buchbinder, S; Feinberg, M; Harrer, E; Harrer, T; Johnson, RP; Walker, BD | 1 |
| Jablonowski, H | 1 |
| Adams, O; Jablonowski, H; Mauss, S; Willers, R | 1 |
| LaCasse, RA; North, TW; Remington, KM | 1 |
| Chambers, DE; Cooper, DA; Crowe, S | 1 |
| Detels, R; Graham, NM; Hoover, DR; Mellors, JW; Park, LP; Phair, JP; Saah, AJ; Stein, DS | 1 |
| Besley, D; Graham, NM; Jacobson, LP; Muñoz, A; Murphy, R; Park, LP; Zucconi, S | 1 |
| Cooper, DA; Harrigan, PR; Kinghorn, I; Lange, JM; Larder, BA; Lavelle, J; Lefkowitz, L; McKinnis, R; Moore, M; Mulder, JW; Pennington, KN; Ramirez-Ronda, C; Rooney, JF; Schooley, RT; St Clair, M; Steel, H | 1 |
| Chaisson, RE; Fortgang, I; Keruly, J; Moore, RD | 1 |
| de Mendonça, JS | 1 |
| Costes, O; Lafeuillade, A; Poggi, C; Profizi, N; Tamalet, C | 1 |
| Bloor, S; Harrigan, PR; Kemp, SD; Kohli, A; Lange, JM; Larder, BA; Pennington, KN; Schooley, RT; St Clair, MH | 1 |
| Childress, JF; DeMets, DL; Ellenberg, SS; Fleming, TR; Foulkes, M; Mayer, KH; O'Fallon, J; Pollard, RB; Rahal, JJ; Whitley, RJ | 1 |
| Cox, S; Harmenberg, J; Palmer, S | 1 |
| Abraham, T; Nusbaum, NJ | 1 |
| Boulton, A | 1 |
| André, E; Bez, G; Bourdillon, F; Delfraissy, JF; Nadal, JM | 1 |
| Ho, DD | 1 |
| Chikami, GK; Piazza-Hepp, TD; Styrt, BA | 1 |
| Abrams, D; Collins, G; Crane, L; Hodges, JS; Loveless, MO; Markowitz, N; Pettinelli, C; Reves, R; Saravolatz, LD; Stein, DS; Thompson, M; Winslow, DL | 1 |
| Corey, L; Holmes, KK | 1 |
| Lane, HC; Masur, H; Spooner, KM | 1 |
| Medlin, HK; North, TW; Phillips, TR; Remington, KM; Zhu, YQ | 1 |
| Canivet, M; Molina, JM; Peries, J; Santillana-Hayat, M; Valla, J | 1 |
| Ayisi, NK | 1 |
| Cohen, LG; Noormohamed, SE | 1 |
| Carr, A; Cooper, DA; Emery, S; Kelleher, A; Law, M | 1 |
| Ambetima, N; Blanquet, D; Hallard, M; Mathé, G; Morette, C; Orbach-Arbouys, S; Pontiggia, P; Triana, K | 1 |
| Barber, CG; Hogg, R; Montaner, JS; Murphy, C; O'Shaughnessy, M; Phillips, P; Schechter, MT; Srour, LF | 1 |
| Baba, M; Hashimoto, KI; Okamoto, M; Shigeta, S; Tsunoda, R | 1 |
| Zaretsky, MD | 1 |
| De Simone, C; Famularo, G; Longo, A; Marcellini, S; Moretti, S; Santini, G; Trinchieri, V; Tzantzoglou, S | 1 |
| Millard, PS | 1 |
| Bechtel, LM; Starich, GH; Whitfield, RM | 1 |
| Gatell, JM; Guerra, L; Pérez-Elías, MJ; Santamaría, JM | 1 |
| Antela, A; Parras, F; Podzamczer, D; Ruiz, I | 1 |
| Aguirrebengoa, K; Mallolas, J; Torres Tortosa, M; Uriz, J | 1 |
| Bascuñana, A; Laguna, F; Ocaña, I; Pulido, F | 1 |
| Gatell-Artigas, JM | 1 |
| Augenbraun, M; Minkoff, H | 1 |
| Cui, L; Locatelli, L; Sommadossi, JP; Xie, MY | 1 |
| Caruz, A; Leal, M; Lissen, E; Rey, C | 1 |
| Hirschel, B; Rutschmann, O | 1 |
| Heins, JR | 1 |
| Craig, C; Moyle, G | 1 |
| Ammi-Saïd, M; Barlovatz-Meimon, G; Benbrik, E; Bonavaud, S; Chariot, P; Frisdal, E; Gherardi, R; Rey, C | 1 |
| Brizzi, M; Ceccherini-Nelli, L; Forastieri, G; Iuliano, R; Mazzotta, F; Mecocci, L | 1 |
| Bonsel, GJ; Danner, SA; Lange, JM; Reiss, P; van Leeuwen, R | 1 |
| Böhler, T; Debatin, KM; Geiss, M; Haas, J; Herr, I | 1 |
| Collins, DO; Sakamoto, A | 1 |
| Roca, B; Simón, E | 1 |
| Boucher, C; Brun-Vézinet, F; Descamps, D; Fauveau, V; Izopet, J; Jeffries, D; Kaye, S; Krzyanowski, C; Loveday, C; Nunn, A; Schuurman, R; Seigneurin, JM; Tamalet, C; Tedder, R; Weber, J; Weverling, GJ | 1 |
| Back, DJ; Barry, MG; Hoggard, PG; Kewn, S; Veal, GJ | 1 |
| Izopet, J; Marchou, B; Massip, P; Pasquier, C; Puel, J; Sandres, K; Tamalet, C | 1 |
| Kavlick, MF; Kosalaraksa, P; Mitsuya, H; Yusa, K | 1 |
| Back, DJ; Barry, MG; Hoggard, PG; Manion, V | 1 |
| Barton, S; Blaxhult, A; Clotet, B; Goebel, FD; Hirschel, B; Katlama, C; Lundgren, JD; Pedersen, C; Phillips, AN; Vella, S | 1 |
| Byington, R; Elbeik, T; Fiscus, SA; Griffith, BP; Hammer, SM; Hughes, MD; Jackson, B; Japour, A; Katzenstein, DA; Lathey, JL; Pi, T; Rasheed, S; Reichman, R; Scott, W | 1 |
| Brettle, RP; Gore, S; Hutchinson, S; Leen, CL; Lewis, S; Morgan, R; Morris, S; Povey, S; Wilson, A | 1 |
| Conway, B; Hogg, RS; Montaner, JS; O'Shaughnessy, MV; Rhone, SA; Schechter, MT; Sherlock, C; Yip, B | 1 |
| DeMasi, R; Hill, AM; Montaner, JS | 1 |
| Maeda, Y; Mitsuya, H; Venzon, DJ | 1 |
| Kavlick, MF; Mitsuya, H; Wyvill, K; Yarchoan, R | 1 |
| Blanchard, G; Blum, L; Calvo, F; Danne, O; Lebbé, C; Morel, P; Pellet, C; Vérola, O | 1 |
| Bloor, S; de Béthune, MP; Gröschel, B; Harrigan, PR; Hertogs, K; Kemp, SD; Larder, BA; Miller, V; Pauwels, R; Staszewski, S; Stürmer, M | 1 |
| Bloch, J; Chavance, M | 1 |
| Bridges, EG; Cheng, YC; Dutschman, GE; Gullen, E; Guo, X; Kukhanova, M; Liu, SH | 1 |
| Clotet, B; Gómez-Cano, M; Leal, M; Pérez-Olmeda, M; Pineda, JA; Puig, T; Rubio, A; Ruiz, L; Soriano, V; Xaus, N; Zamora, L | 1 |
| Baldeweg, T; Catalan, J; Gazzard, BG | 1 |
| Clotet, B; De Clercq, E; Desmyter, J; Puig, T; Rossau, R; Ruiz, L; Schmit, JC; Stuyver, L; Van Laethem, K; Vandamme, AM; Vanderlinden, I | 1 |
| Font, E; Lasanta, S; Rodríguez, JF; Rosario, O | 1 |
| Boucher, CA; Bruisten, SM; Huisman, JG; Loeliger, AE; Reiss, P; Schuurman, R; van Swieten, P; Weverling, GJ | 1 |
| Clotet, B; Cruceta, A; García, F; Gatell, JM; Leal, M; Mallolas, J; Miró, JM; Pumarola, T; Ruiz, L; Tortajada, C; Vidal, C | 1 |
| Bachmeyer, C; Blum, L | 1 |
| Belec, L; Cotigny, S; Gilquin, J; Gutmann, L; Kazatchkine, M; Matta, M; Piketty, C; Si Mohamed, A; Weiss, L | 1 |
| Kempf-Durepaire, G; Krantz, V; Lang, JM; Nicolle, M; Partisani, M; Rey, D; Schmitt, AC; Schmitt, MP | 1 |
| Saag, MS; Schooley, RT | 1 |
| Arnedo, A; Mínguez, C; Olmos, P; Roca, B; Sáez-Royuela, A; Segarra, M; Simón, E; Teruel, C; Usó, J | 1 |
| Coolley, KL; Girard, YA; Hamdan, H; Katzenstein, DA; Levee, DJ; Merigan, TC; Shafer, RW; Winters, MA | 1 |
| Balfour, HH; Erice, A; Fischl, MA; Henry, K; Hirsch, MS; Kahn, JO; Kenton, A; Kmack, A; Liou, SH; Martinez, A; Phair, J; Tierney, C | 1 |
| Ippolito, G; Puro, V | 1 |
| Gitterman, SR; Pratt, RD; Struble, KA | 1 |
| Blaschke, TF; Girard, P; Kastrissios, H; Katzenstein, D; Sheiner, LB; Suárez, JR | 1 |
| Blaschke, TF; Hammer, S; Kastrissios, H; Katzenstein, D; Suárez, JR | 1 |
| Moyle, GJ; Sadler, M | 1 |
| Fleury, S; Miedema, F; Otto, SA; Reiss, P; ten Kate, RW; van der Zee, AG; Wisman, GB; Wolthers, KC | 1 |
| Phillips, L | 1 |
| Flandre, P | 1 |
| Armitage, P | 1 |
| Djomand, G; Lackritz, EM; Mbidde, E; Weidle, PJ | 1 |
| Cross, A; Dunkle, L; Kelleher, T | 1 |
| Martin, EM; Mullane, KM; Novak, RM; Pitrak, DL; Pursell, KJ | 1 |
| Temesgen, Z; Wright, AJ | 1 |
| Arlotto, C; Bernard, A; Bernard-Pomier, G; Breittmayer, JP; Dellamonica, P; Pradier, C; Pugliese, P; Roger, PM | 1 |
| Arrizabalaga, J; Clotet, BG; Cruceta, A; Dalmau, D; Gallart, T; García, F; Gatell, JM; Gomez-Sirvent, JL; Grau, I; Knobel, H; Miró, JM; O'Brien, WA; Podzamczer, D; Pumarola, T; Romeu, J; Sambeat, MA | 1 |
| Flepp, M; Jost, J; Ledergerber, B; Opravil, M; Paris, D; Ruef, C; Weber, R; Zimmerli, S | 1 |
| Clotet, B; Gómez-Cano, M; Leal, M; Pérez-Olmeda, M; Puig, T; Rey, C; Rubio, A; Ruiz, L; Soriano, V; Xaus, N; Zamora, L | 1 |
| Briones, C; Soriano, V | 1 |
| Cauda, R; Citton, R; Donati, KG; Leone, F; Spanu, T; Tacconelli, E; Tumbarello, M | 1 |
| Degenhardt, E; Glück, T; Grossmann, J; Lang, B; Schölmerich, J; Straub, RH | 1 |
| Clotet, B; De Clercq, E; Desmyter, J; Evans, C; Hermans, P; Muyldermans, G; Ruiz, L; Schmit, JC; Schneider, F; Simons, P; Stuyver, L; Van Laethem, K; Van Vaerenbergh, K; Van Wanzeele, F; Van Wijngaerden, E; Vandamme, AM; Verhofstede, C | 1 |
| Babiker, A; Collins, R; Darbyshire, J; Duncan, W; Foulkes, M; Hughes, M; Peto, R; Peto, T; Walker, A | 2 |
| Allende, MC; Belloso, WH; Benetucci, JA; Cahn, PE; Davey, RT; Emery, S; Lane, HC; Lasala, MC; Law, MG; Lopardo, G; Losso, MH; Nelson, E; Salomon, H; Saracco, M | 1 |
| Beylot, J; Dabis, F; Dequae-Merchadou, L; Marimoutou, C; Mercié, P; Morlat, P; Neau, D; Pellegrin, I | 1 |
| Ait-Khaled, M; Griffin, P; Kleim, JP; Rakik, A; Thomas, TA; Tisdale, M | 1 |
| Boschini, A; Calista, D | 1 |
| Fujinaga, M; Holodniy, M; Schulte, M | 1 |
| García-Lerma, JG; Gerrish, PJ; Heneine, W; Qari, SH; Wright, AC | 1 |
| Cotton, DJ; Currier, JS; Grimes, J; Hammer, SM; Hughes, MD; Katzenstein, DA; Spino, C; Wofsy, CB | 1 |
| Albrecht, MA; Balfour, HH; Hammer, SM; Hughes, MD; Katzenstein, DA; Liou, SH; Murphy, R; Para, MF; Valdez, H | 1 |
| La Seta Catamancio, S; Parker, D; Rusconi, S; Sheridan, F | 1 |
| Davis, C; Heredia, A; Redfield, R | 1 |
| Arendt, G; Hefter, H; Theisen, A; von Giesen, HJ | 1 |
| Hirsch, MS; Yeni, P | 1 |
| Gilden, D | 1 |
| Poscher, M | 2 |
| Japour, AJ | 1 |
| Vella, S | 1 |
| James, JS | 5 |
| Levin, J | 1 |
| King, E | 1 |
| Torres, G | 3 |
| Smart, T | 4 |
| Mascolini, M | 1 |
| Coombs, R; Cotton, D; Hammer, S; Saag, M; van der Horst, C | 1 |
| Cheng, B | 2 |
| Alcorn, K | 1 |
| Folkers, G | 1 |
| Cooper, EC | 1 |
| Randall, P | 1 |
| Doepel, L; Folkers, G | 1 |
| MacDougall, DS | 1 |
| Cain, D; Clarke, JR; Erlwein, O; Frater, AJ; Grigg, AR; Hill, CL; McClure, MO; Patton, G; Rosenblum, LL | 1 |
| Dickman, K; Lake-Bakaar, G; Lyubsky, S; Mazzoccoli, V | 1 |
| Blumoff, K; Garcia-Lerma, JG; Heneine, W; Nidtha, S; Weinstock, H | 1 |
| Blanquet, D; Hage, F; Hallard, M; Mathe, G; Morette, C; Pontiggia, P | 1 |
| Birkus, G; Cihlar, T; Greenwalt, DE; Hitchcock, MJ | 1 |
| Babiker, A; Darbyshire, J; Dunn, D; Hooker, M | 1 |
| Böckenholt, S; Evers, S; Frese, A; Frohne, L; Heese, C; Husstedt, IW; Rahmann, A; Reichelt, D | 1 |
| Baldwin, SA; Cass, CE; Loewen, SK; Ng, AM; Yao, SY; Young, JD | 1 |
| Brůcková, M; Linka, M; Reinis, M; Stanková, M; Vandasová, J | 1 |
| Domínguez Castellanos, A; Justo Alpañés, E; Orbea Ríos, L | 1 |
| Bates, M; Chappey, C; Hellmann, NS; Maroldo, L; Parkin, N; Petropoulos, CJ | 1 |
| Bettendorf, DM; Christopherson, C; D'Aquila, RT; Hammer, SM; Katzenstein, DA; Lathey, JL; Tierney, C | 1 |
| Aboulker, JP; Brun-Vézinet, F; Descamps, D; Flandre, P; Izopet, J; Joly, V; Meiffrédy, V; Tamalet, C | 1 |
| Bacheler, L; Erickson-Viitanen, S; Gallagher, K; Garber, S; Geleziunas, R; Otto, MJ; Schinazi, RF; Shi, G; Wu, JT; Zhang, H | 1 |
| Macher, A; Paul, SM; Thomas, D | 1 |
| Casula, M; de Ronde, A; Goudsmit, J; Lange, JM; Reiss, P; Weverling, GJ | 1 |
| Bäuerle, J; Gatell, JM; Laguno, M; Mallolas, J; Mauss, S; Miquel, R; Murillas, J; Schmutz, G; Setzer, B; Walker, UA | 1 |
| Bates, M; Chappey, C; Clair, MS; Fisher, R; Lanier, ER; Parkin, N; Ross, L; Tisdale, M | 1 |
| Brachman, EE; Kmiec, EB | 1 |
| Schlesier, M; Setzer, B; Thomas, AK; Walker, UA | 1 |
| Baker, SG; Fitzmaurice, GM; Freedman, LS; Kramer, BS | 1 |
| de Baar, MP; de Ronde, A; Ruiter, JP; Tebas, P; Timmermans, EC; Wanders, RJ | 1 |
| Bacheler, L; Koontz, D; Mellors, JW; Parikh, UM | 1 |
| Karandreas, N; Kokotis, PI; Konstantinou, K; Kontos, AN; Kordossis, T; Panayiotakopoulos, GD; Skopelitis, EE | 1 |
| Johnston, E; Kassaye, SG; Katzenstein, DA; Shulman, NS; Winters, MA | 1 |
| Arenas-Pinto, A; Bhaskaran, K; Dunn, D; Weller, IV | 1 |
| Ghosh, D | 1 |
| Couvreur, P; Desmaële, D; Gref, R | 1 |
| Fields, E; Koczor, CA; Lewis, W; White, RC; Zhao, P; Zhu, L | 1 |
| Andrieux, K; Argote, S; Bauduin, L; Bekkara-Aounallah, F; Caron, J; Clayette, P; Couvreur, P; Dereuddre-Bosquet, N; Desmaële, D; Gref, R; Hillaireau, H; Lepêtre, S; Rogez-Kreuz, C; Rousseau, B; Skanji, R; Yousfi, R | 1 |
| Brul, S; de Boer, R; De Vos, WH; Manders, EM; Smith, RL; van der Spek, H | 1 |
| Arnold, E; Das, K; Martinez, SE | 1 |
| Abad-Carrillo, MA; Álvarez-Ríos, AI; Bernal-Morell, E; Genebat, M; González-García, J; Herrero-Fernández, I; Leal, M; Montero, M; Pacheco, YM; Pulido, F; Rosado-Sánchez, I; Ruiz-Mateos, E; Vidal, F | 1 |
| Fernández, S; Ferrero, M; Martín-Nieves, V; Sanghvi, YS | 1 |
74 review(s) available for zalcitabine and didanosine
| Article | Year |
|---|---|
Natural product-based anti-HIV drug discovery and development facilitated by the NCI developmental therapeutics program.
Topics: Amino Acid Sequence; Anti-HIV Agents; HIV-1; Models, Biological; Models, Chemical; Molecular Sequence Data; National Institutes of Health (U.S.); Retrospective Studies; United States; Virus Replication | 2001 |
[New therapeutic trends in AIDS].
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Deoxyadenosines; Didanosine; Dideoxynucleosides; Humans; Poly I-C; Poly U; Randomized Controlled Trials as Topic; Ribavirin; RNA, Double-Stranded; Zalcitabine; Zidovudine | 1992 |
New developments in antiretroviral drug therapy for HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Didanosine; Drug Combinations; Drug Therapy, Combination; Gene Products, tat; HIV Infections; HIV-1; Humans; Protease Inhibitors; tat Gene Products, Human Immunodeficiency Virus; Zalcitabine; Zidovudine | 1992 |
Anti-human immunodeficiency virus therapeutics: now and the future.
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Dideoxynucleosides; HIV; HIV-1; Humans; Trichosanthin; Zalcitabine; Zidovudine | 1992 |
The use of nucleoside analogues in the treatment of HIV-infected children.
Topics: Child; Child, Preschool; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Infant; Infant, Newborn; Zalcitabine; Zidovudine | 1992 |
Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: combination therapy.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Didanosine; Drug Evaluation; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Zalcitabine; Zidovudine | 1992 |
Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: adverse effects.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Zalcitabine; Zidovudine | 1992 |
Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: monotherapy.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Didanosine; Drug Resistance, Microbial; HIV Infections; HIV-1; Humans; Time Factors; Zalcitabine; Zidovudine | 1992 |
HIV disease: therapy, related systemic and oral conditions--an update.
Topics: Acquired Immunodeficiency Syndrome; Bacterial Infections; Didanosine; HIV Infections; Humans; Mouth Diseases; Mycoses; Sarcoma, Kaposi; Virus Diseases; Zalcitabine; Zidovudine | 1992 |
Current status of therapy for human immunodeficiency virus type 1.
Topics: CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Didanosine; Drug Resistance; HIV Infections; HIV Seropositivity; HIV-1; Humans; T-Lymphocytes, Helper-Inducer; Zalcitabine; Zidovudine | 1992 |
[Anti-HIV treatment, today and in the near future].
Topics: Antiviral Agents; Didanosine; Dideoxynucleosides; DNA, Viral; Drug Therapy, Combination; HIV Infections; Humans; Reverse Transcriptase Inhibitors; Stavudine; Transcription, Genetic; Zalcitabine; Zidovudine | 1992 |
[Treatments of human immunodeficiency virus infection. Current developments].
Topics: Acquired Immunodeficiency Syndrome; Didanosine; HIV; HIV Infections; Humans; Zalcitabine; Zidovudine | 1991 |
New developments in dideoxynucleoside antiretroviral therapy for HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Dideoxynucleosides; HIV Infections; Humans; Zalcitabine; Zidovudine | 1991 |
HIV/AIDS pathogenesis and treatment: new twists and turns.
Topics: Acquired Immunodeficiency Syndrome; CD4-Positive T-Lymphocytes; Didanosine; Humans; Lymphocyte Depletion; Trichosanthin; Zalcitabine; Zidovudine | 1991 |
Chemotherapy of human immunodeficiency virus infections: current practice and future prospects.
Topics: Animals; Antiviral Agents; Didanosine; DNA Nucleotidyltransferases; DNA Replication; Drug Therapy, Combination; Endopeptidases; HIV Infections; HIV-1; Humans; Integrases; RNA-Directed DNA Polymerase; Virus Replication; Zalcitabine; Zidovudine | 1990 |
Targeted therapy of human immunodeficiency virus-related disease.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Antiviral Agents; CD4 Antigens; Didanosine; Dideoxynucleosides; Dipyridamole; Drug Synergism; Gene Expression Regulation, Viral; Genes, nef; Genes, rev; Genes, tat; HIV; HIV Protease; Interferon Type I; Organophosphonates; RNA-Directed DNA Polymerase; Stavudine; Transcription, Genetic; Zalcitabine; Zidovudine | 1991 |
Anti-retroviral therapy of human immunodeficiency virus infection: current strategies and challenges for the future.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Didanosine; Drug Resistance; HIV; HIV Infections; Humans; Lymphoma, Non-Hodgkin; Retroviridae; Reverse Transcriptase Inhibitors; T-Lymphocytes, Helper-Inducer; Virus Replication; Zalcitabine; Zidovudine | 1991 |
Zidovudine and other reverse transcriptase inhibitors in the management of human immunodeficiency virus-related disease.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Child; Didanosine; Female; Foscarnet; HIV Infections; Humans; Phosphonoacetic Acid; Pregnancy; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1991 |
Treatment of AIDS with combinations of antiretroviral agents.
Topics: Acquired Immunodeficiency Syndrome; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Humans; Interferon Type I; Recombinant Proteins; Zalcitabine; Zidovudine | 1991 |
Update on reverse transcriptase inhibitors in HIV disease.
Topics: Acquired Immunodeficiency Syndrome; Clinical Trials as Topic; Didanosine; Humans; Prognosis; Reverse Transcriptase Inhibitors; Risk Factors; Zalcitabine; Zidovudine | 1993 |
[Reverse transcriptase inhibitors as anti-HIV agents].
Topics: Amino Acid Sequence; Antiviral Agents; Didanosine; Drug Resistance, Microbial; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Protein Conformation; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Zalcitabine; Zidovudine | 1993 |
Resistance of human immunodeficiency virus type 1 to antiretroviral agents: a review.
Topics: Antiviral Agents; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Microbial Sensitivity Tests; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1994 |
Combination therapy for infection due to human immunodeficiency virus type 1.
Topics: Acyclovir; Antiviral Agents; CD4 Antigens; Clinical Trials as Topic; Combined Modality Therapy; Didanosine; Drug Therapy, Combination; Foscarnet; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; In Vitro Techniques; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1994 |
Survival effects of ZDV, ddI, and ddC in patients with CD4 < or = 50 cells/mm3.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Didanosine; Double-Blind Method; HIV Infections; Humans; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Zalcitabine; Zidovudine | 1995 |
Mitochondrial toxicity of antiviral drugs.
Topics: Acquired Immunodeficiency Syndrome; Animals; Antiviral Agents; Arabinofuranosyluracil; Didanosine; DNA-Directed DNA Polymerase; DNA, Mitochondrial; Humans; Mitochondria; Zalcitabine; Zidovudine | 1995 |
Pharmacokinetic optimisation of antiretroviral therapy in patients with HIV infection.
Topics: Aging; Antineoplastic Agents; Antiviral Agents; Didanosine; Drug Interactions; Guidelines as Topic; HIV Infections; Humans; Phosphorylation; Racial Groups; Sex Characteristics; Stavudine; Zalcitabine; Zidovudine | 1995 |
An approach to antiretroviral treatment of HIV disease. Nucleoside monotherapy.
Topics: Antiviral Agents; Didanosine; HIV Infections; HIV-1; Humans; Lamivudine; Nucleosides; Stavudine; Zalcitabine; Zidovudine | 1995 |
Human immunodeficiency virus infection in children.
Topics: Adolescent; AIDS-Related Opportunistic Infections; Child; Child, Preschool; Dapsone; Didanosine; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Pentamidine; Pneumonia, Pneumocystis; Pregnancy; Pregnancy Complications, Infectious; Recurrence; Stavudine; Trimethoprim, Sulfamethoxazole Drug Combination; Zalcitabine; Zidovudine | 1995 |
Clinical pharmacology of zidovudine and other 2',3'-dideoxynucleoside analogues.
Topics: Acquired Immunodeficiency Syndrome; Adult; Child; Didanosine; Dideoxynucleosides; Drug Interactions; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Interferons; Needlestick Injuries; Sarcoma, Kaposi; Zalcitabine; Zidovudine | 1993 |
[Anti-HIV therapy (1987-1994): from nothing to confusion].
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Time Factors; Zalcitabine; Zidovudine | 1995 |
Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection.
Topics: Animals; Didanosine; Dideoxynucleosides; Disease Models, Animal; HIV Infections; Humans; Peripheral Nervous System Diseases; Stavudine; Zalcitabine | 1995 |
Controversies in anti-retroviral therapy of adults.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; AIDS-Related Complex; AIDS-Related Opportunistic Infections; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Drug Tolerance; HIV Infections; HIV-1; Humans; Zalcitabine; Zidovudine | 1995 |
Pancreatic lesions in HIV-infected patients.
Topics: Acute Disease; AIDS-Related Opportunistic Infections; Didanosine; HIV Infections; Humans; Pancreas; Pancreatic Diseases; Pancreatitis; Pentamidine; Trimethoprim, Sulfamethoxazole Drug Combination; Zalcitabine | 1994 |
Antiretroviral therapy for children.
Topics: Acquired Immunodeficiency Syndrome; Adult; Child; Clinical Trials as Topic; Controlled Clinical Trials as Topic; Didanosine; DNA, Viral; Drug Resistance, Microbial; HIV-1; Humans; Immunity, Cellular; Virus Replication; Zalcitabine; Zidovudine | 1994 |
HIV therapy advances. Pediatric antiretroviral choices.
Topics: Body Weight; Clinical Trials as Topic; Didanosine; Female; Growth; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Pregnancy; Pregnancy Complications, Infectious; Treatment Failure; Zalcitabine; Zidovudine | 1994 |
Future treatment strategies in HIV infection.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; Antiviral Agents; Biomarkers; CD4 Lymphocyte Count; Didanosine; Forecasting; HIV Infections; Humans; Zalcitabine; Zidovudine | 1994 |
Clinical pharmacokinetics of nucleoside antiretroviral agents.
Topics: Animals; Didanosine; Dideoxynucleosides; HIV Infections; Humans; Lamivudine; Stavudine; Zalcitabine; Zidovudine | 1995 |
Antiretroviral therapy for adult HIV-infected patients. Recommendations from a state-of-the-art conference. National Institute of Allergy and Infectious Diseases State-of-the-Art Panel on Anti-Retroviral Therapy for Adult HIV-Infected Patients.
Topics: Adult; CD4-Positive T-Lymphocytes; Clinical Trials as Topic; Didanosine; Dideoxynucleosides; Drug Resistance; Guidelines as Topic; HIV Infections; Humans; Leukocyte Count; Zalcitabine; Zidovudine | 1993 |
Management of antiretroviral drug therapy in human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Didanosine; HIV-1; Humans; Retroviridae Infections; Zalcitabine; Zidovudine | 1994 |
Antiretroviral therapy for human immunodeficiency virus infection: hope and despair.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Didanosine; Humans; In Vitro Techniques; Zalcitabine; Zidovudine | 1994 |
[Antiretroviral therapy. Current status and perspectives].
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV; HIV Infections; Humans; Stavudine; Zalcitabine; Zidovudine | 1994 |
Adverse effects and drug interactions of clinical importance with antiviral drugs.
Topics: Acyclovir; AIDS-Related Opportunistic Infections; Amantadine; Antiviral Agents; Didanosine; Drug Interactions; Foscarnet; Ganciclovir; Humans; Interferon-alpha; Ribavirin; Rimantadine; Vidarabine; Zalcitabine; Zidovudine | 1994 |
Perspectives on the use of antiretroviral drugs in the treatment of HIV infection.
Topics: Didanosine; Dideoxynucleosides; Drug Administration Schedule; HIV Infections; Humans; Stavudine; Zalcitabine; Zidovudine | 1994 |
Zalcitabine and didanosine.
Topics: Adult; Antiviral Agents; Child; Didanosine; DNA Replication; DNA, Viral; Drug Interactions; HIV; HIV Infections; Humans; Virus Replication; Zalcitabine | 1993 |
[Therapy of HIV infection with nucleoside analogs].
Topics: Antiviral Agents; Didanosine; Drug Therapy, Combination; HIV; HIV Infections; Humans; Nucleosides; Zalcitabine; Zidovudine | 1993 |
[Is resistance of human immunodeficiency viruses (HIV) to nucleoside analogs an indication for their combined use?].
Topics: Acyclovir; Didanosine; Drug Synergism; Drug Therapy, Combination; Female; Foscarnet; HIV-1; Humans; In Vitro Techniques; Male; Ribavirin; Zalcitabine; Zidovudine | 1993 |
Therapy for human immunodeficiency virus infection.
Topics: Didanosine; Drug Resistance; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Protease Inhibitors; Zalcitabine; Zidovudine | 1993 |
Current use of anti-HIV drugs in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Drug Therapy, Combination; Humans; Zalcitabine; Zidovudine | 1993 |
Antiretroviral therapy of human immunodeficiency virus type-1 (HIV-1) infection.
Topics: Antiviral Agents; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 1995 |
Studies of zidovudine in combination with didanosine and zalcitabine.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Disease Progression; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; Humans; Reverse Transcriptase Inhibitors; Safety; Zalcitabine; Zidovudine | 1995 |
Managing HIV. Part 4: Primary therapy. 4.1 Antiretroviral therapies for HIV.
Topics: Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Multicenter Studies as Topic; Zalcitabine; Zidovudine | 1996 |
Clinical toxicity of antiretroviral nucleoside analogs.
Topics: Animals; Antiviral Agents; Didanosine; Humans; Lamivudine; Mitochondria; Nucleosides; Stavudine; Zalcitabine; Zidovudine | 1996 |
Guide to major clinical trials of antiretroviral therapy administered to patients infected with human immunodeficiency virus.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Meta-Analysis as Topic; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 1996 |
Pediatric HIV infection: a primer for pharmacists.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Didanosine; Female; HIV Infections; Humans; Infant; Infant, Newborn; Male; Pharmacists; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1996 |
[Initial anti-retroviral treatment (therapeutic approach to patients without previous treatment)].
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; HIV Infections; Humans; Zalcitabine; Zidovudine | 1996 |
[Anti-retroviral treatment. Approach to previously treated patients].
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Zalcitabine; Zidovudine | 1996 |
[Nucleoside analogs inhibiting reverse transcriptase: use in adult patient with HIV infection].
Topics: Adult; Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 1996 |
[Anti-retroviral treatment. Treatment modification: toxicity management].
Topics: Anti-HIV Agents; Didanosine; Drug Eruptions; Drug Therapy, Combination; Gastrointestinal Diseases; Hematologic Diseases; HIV Infections; Humans; Muscular Diseases; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1996 |
[Antiretroviral treatment. Present and future of the combinations].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; HIV-1; Humans; Zalcitabine; Zidovudine | 1996 |
Antiretroviral therapy for pregnant women.
Topics: Anti-HIV Agents; Didanosine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Pregnancy; Pregnancy Complications, Infectious; Ritonavir; Saquinavir; Zalcitabine; Zidovudine | 1997 |
Antiretroviral therapy: a guide to the most important trials.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; Nevirapine; Pyridines; Ritonavir; Saquinavir; Stavudine; Viral Load; Zalcitabine; Zidovudine | 1997 |
The development of resistance of HIV-1 to zalcitabine.
Topics: Amino Acids; Anti-HIV Agents; Didanosine; Drug Resistance, Microbial; Genetic Variation; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Models, Molecular; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Zalcitabine | 1997 |
[Antiretroviral treatment in human immunodeficiency virus infection].
Topics: Antiviral Agents; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Ritonavir; Saquinavir; Stavudine; Treatment Outcome; Viral Load; Zalcitabine; Zidovudine | 1997 |
Antiretroviral chemotherapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1998 |
Toxicity of antiretroviral agents.
Topics: Anti-HIV Agents; Didanosine; Health Personnel; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Occupational Exposure; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1997 |
Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management.
Topics: Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Peripheral Nervous System Diseases; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 1998 |
Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta-analyses of the randomised evidence. HIV Trialists' Collaborative Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Didanosine; Disease Progression; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Randomized Controlled Trials as Topic; Survival Rate; Time Factors; Zalcitabine; Zidovudine | 1999 |
Relation of peripheral neuropathy to HIV treatment in four randomized clinical trials including didanosine.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Child, Preschool; Data Collection; Didanosine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Female; Humans; Male; Middle Aged; Peripheral Nervous System Diseases; Polypharmacy; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Zalcitabine; Zidovudine | 1999 |
Antiretrovirals.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; Female; Furans; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Pregnancy; Pregnancy Complications, Infectious; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; Sulfonamides; Zalcitabine; Zidovudine | 1999 |
Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; Humans; Zalcitabine; Zidovudine | 2000 |
Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; Humans; Randomized Controlled Trials as Topic; Zalcitabine; Zidovudine | 2000 |
Antiretroviral agents.
Topics: Acyclovir; Animals; Antiviral Agents; Carcinogens; Didanosine; Disease Models, Animal; Evidence-Based Medicine; Humans; Intestinal Absorption; Neoplasms; Risk Factors; Tissue Distribution; Zalcitabine; Zidovudine | 2000 |
Contraindicated antiretroviral drug combinations.
Topics: Anti-Retroviral Agents; Contraindications; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Saquinavir; Stavudine; Zalcitabine | 2003 |
Squalenoylation: a generic platform for nanoparticular drug delivery.
Topics: Animals; Antineoplastic Agents; Antiviral Agents; Deoxycytidine; Didanosine; Drug Delivery Systems; Gemcitabine; Humans; Nanoparticles; Squalene; Zalcitabine | 2012 |
54 trial(s) available for zalcitabine and didanosine
| Article | Year |
|---|---|
WSU part of national study to test AIDS therapies.
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Humans; Michigan; Zalcitabine | 1991 |
Henry Ford begins clinical trial of two new AIDS therapies.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Didanosine; Humans; Zalcitabine | 1991 |
Chemotherapy of human immunodeficiency virus infections: current practice and future prospects.
Topics: Animals; Antiviral Agents; Didanosine; DNA Nucleotidyltransferases; DNA Replication; Drug Therapy, Combination; Endopeptidases; HIV Infections; HIV-1; Humans; Integrases; RNA-Directed DNA Polymerase; Virus Replication; Zalcitabine; Zidovudine | 1990 |
Treatment of AIDS with combinations of antiretroviral agents.
Topics: Acquired Immunodeficiency Syndrome; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Humans; Interferon Type I; Recombinant Proteins; Zalcitabine; Zidovudine | 1991 |
Effects of antiretroviral dideoxynucleosides on polymorphonuclear leukocyte function.
Topics: Cell Survival; Chemotaxis, Leukocyte; Didanosine; HIV Infections; HIV-1; Humans; Neutrophils; Phagocytosis; Superoxides; Zalcitabine; Zidovudine | 1990 |
FDA expands testing of anti-AIDS drugs.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS Dementia Complex; AIDS-Related Complex; Antiviral Agents; Clinical Trials as Topic; Didanosine; Humans; Infant; Infant, Newborn; United States; United States Food and Drug Administration; Zalcitabine; Zidovudine | 1989 |
Insights from monitoring the CPCRA didanosine/zalcitabine trial. Terry Beirn Community Programs for Clinical Research on AIDS.
Topics: Antiviral Agents; Biomarkers; CD4 Lymphocyte Count; Confidence Intervals; Didanosine; Disease Progression; Drug Monitoring; HIV Infections; Humans; National Institutes of Health (U.S.); Prognosis; Randomized Controlled Trials as Topic; Research Design; Severity of Illness Index; United States; Zalcitabine | 1995 |
Treatment options in zidovudine intolerance or failure.
Topics: Acquired Immunodeficiency Syndrome; Adult; Didanosine; Female; Follow-Up Studies; Humans; Male; Survival Rate; Time Factors; Treatment Failure; Zalcitabine; Zidovudine | 1994 |
A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; CD4-Positive T-Lymphocytes; Didanosine; Female; Follow-Up Studies; HIV Infections; Humans; Leukocyte Count; Male; Risk; Zalcitabine; Zidovudine | 1994 |
Response of CD4 lymphocytes and clinical consequences of treatment using ddI or ddC in patients with advanced HIV infection.
Topics: Antiviral Agents; Biomarkers; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Didanosine; Disease Progression; Follow-Up Studies; HIV Infections; HIV-1; Humans; Regression Analysis; Survival Rate; Treatment Outcome; Zalcitabine | 1996 |
Combination therapy with ZDV + DDI versus ZDV + DDC in patients with progression of HIV-infection under treatment with ZDV.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Survival Analysis; Treatment Outcome; Zalcitabine; Zidovudine | 1996 |
Survival in HIV-infected patients who have received zidovudine: comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy. Multicenter AIDS Cohort Study Group.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; HIV Seropositivity; Humans; Longitudinal Studies; Male; Proportional Hazards Models; Zalcitabine; Zidovudine | 1996 |
Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Male; Middle Aged; Phenotype; RNA, Viral; Zalcitabine; Zidovudine | 1996 |
Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group.
Topics: Antigens, CD; Antiviral Agents; CD4 Antigens; Coculture Techniques; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; Genotype; HeLa Cells; HIV Reverse Transcriptase; HIV Seropositivity; HIV-1; Humans; Lymphocytes; Microbial Sensitivity Tests; Phenotype; Point Mutation; RNA-Directed DNA Polymerase; Zalcitabine; Zidovudine | 1996 |
Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee.
Topics: Adolescent; Adult; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; Humans; Male; Survival Analysis; Zalcitabine; Zidovudine | 1996 |
Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Rese
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Male; Risk; Survival Analysis; Zalcitabine; Zidovudine | 1996 |
CD8+ lymphocyte responses to antiretroviral therapy of HIV infection.
Topics: Acetamides; Acetophenones; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; Humans; Lamivudine; Lymphocyte Count; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load; Zalcitabine; Zidovudine | 1996 |
AIDS therapy with two, three or four agent combinations, applied in short sequences, differing from each other by drug rotation. I. First of two parts: a phase I trial equivalent, concerning five virostatics: AZT, ddI, ddC, acriflavine and an ellipticine
Topics: Acquired Immunodeficiency Syndrome; Acriflavine; Adult; Anti-Infective Agents; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Ellipticines; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Zalcitabine; Zidovudine | 1996 |
Should we embrace new drugs with open arms? Experience from a community-based, open-arm, randomized clinical trial of combination antiretroviral therapy in advanced HIV disease.
Topics: Adult; Anti-HIV Agents; British Columbia; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Patient Selection; Practice Patterns, Physicians'; Prospective Studies; Zalcitabine; Zidovudine | 1996 |
Acetyl-carnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analogues.
Topics: Acetylcarnitine; Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Axons; Cross-Sectional Studies; Didanosine; Female; Humans; Male; Middle Aged; Peripheral Nervous System Diseases; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine | 1997 |
[Effect of treatment with nucleoside analogues in subjects with primary genotypic resistance to zidovudine].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; Drug Resistance; Drug Therapy, Combination; Genotype; HIV-1; Humans; Zalcitabine; Zidovudine | 1996 |
Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial.
Topics: Acetamides; Acetophenones; Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Health Services; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1997 |
Additive or sequential nucleoside analogue therapy compared with continued zidovudine monotherapy in human immunodeficiency virus-infected patients with advanced disease does not prolong survival: an observational study.
Topics: Adult; Age Factors; Anti-HIV Agents; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Middle Aged; Prognosis; Proportional Hazards Models; Survival Rate; Treatment Outcome; Zalcitabine; Zidovudine | 1997 |
HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Double-Blind Method; Drug Resistance, Microbial; Drug Therapy, Combination; Genes, pol; HIV Infections; HIV-1; Humans; Point Mutation; Prospective Studies; RNA, Viral; Viral Load; Zalcitabine; Zidovudine | 1997 |
Quantification of HIV-1 proviral DNA by a standardized colorimetric PCR-based assay.
Topics: Adult; Anti-HIV Agents; Colorimetry; Didanosine; DNA, Viral; Evaluation Studies as Topic; Female; HIV-1; Humans; Indinavir; Lamivudine; Male; Polymerase Chain Reaction; Proviruses; Ritonavir; RNA, Viral; Transcription, Genetic; Zalcitabine; Zidovudine | 1998 |
Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 175 Team.
Topics: Adult; Anti-HIV Agents; Biomarkers; CD4 Lymphocyte Count; Didanosine; Dideoxynucleosides; Disease Progression; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Multivariate Analysis; Prognosis; Reverse Transcriptase Inhibitors; RNA, Viral; Zalcitabine; Zidovudine | 1998 |
Antiviral effect of double and triple drug combinations amongst HIV-infected adults: lessons from the implementation of viral load-driven antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Multivariate Analysis; Stavudine; Viral Load; Zalcitabine; Zidovudine | 1998 |
The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count.
Topics: Acetamides; Acetophenones; Acquired Immunodeficiency Syndrome; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; RNA, Viral; Treatment Outcome; Viral Load; Zalcitabine; Zidovudine | 1998 |
Cellular proviral HIV type 1 DNA load persists after long-term RT-inhibitor therapy in HIV type 1 infected persons.
Topics: Anti-HIV Agents; Base Sequence; Didanosine; DNA Primers; DNA, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Proviruses; Reverse Transcriptase Inhibitors; Viral Load; Zalcitabine; Zidovudine | 1998 |
Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV-1-infected patients.
Topics: Adult; Analysis of Variance; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Female; Giant Cells; HIV Infections; HIV-1; Humans; Linear Models; Male; Middle Aged; Multivariate Analysis; Phenotype; Probability; Reverse Transcriptase Inhibitors; Risk Factors; Time Factors; Viral Load; Zalcitabine; Zidovudine | 1998 |
A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Male; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Zalcitabine; Zidovudine | 1998 |
A trial comparing nucleoside monotherapy with sequential therapy with 3 drugs in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Reverse Transcriptase Inhibitors; Treatment Outcome; Zalcitabine; Zidovudine | 1998 |
A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study T
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV; Humans; Male; Nevirapine; Placebos; Reverse Transcriptase Inhibitors; RNA, Viral; Survival Rate; Time Factors; Zalcitabine; Zidovudine | 1998 |
Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Anti-HIV Agents; Didanosine; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Patient Compliance; Reverse Transcriptase Inhibitors; Time Factors; Zalcitabine; Zidovudine | 1998 |
The extent of non-adherence in a large AIDS clinical trial using plasma dideoxynucleoside concentrations as a marker.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; Anti-HIV Agents; Didanosine; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Patient Compliance; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1998 |
HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: an extended virology study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Male; Predictive Value of Tests; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Viral Load; Zalcitabine; Zidovudine | 1999 |
Relation of peripheral neuropathy to HIV treatment in four randomized clinical trials including didanosine.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Child, Preschool; Data Collection; Didanosine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Female; Humans; Male; Middle Aged; Peripheral Nervous System Diseases; Polypharmacy; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Zalcitabine; Zidovudine | 1999 |
A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-CD8 Ratio; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Palatine Tonsil; Ritonavir; RNA, Viral; Spain; Stavudine; Viremia; Zalcitabine; Zidovudine | 1999 |
A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Didanosine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Indinavir; Injections, Subcutaneous; Interleukin-2; Lamivudine; Lymphocyte Count; Male; Nelfinavir; Nevirapine; Ritonavir; RNA, Viral; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 2000 |
Dual nucleoside regimens in nonadvanced HIV infection: prospective follow-up of 130 patients, Aquitaine Cohort, 1996 to 1998. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA).
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Didanosine; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Multivariate Analysis; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Treatment Outcome; Zalcitabine; Zidovudine | 2000 |
Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The Aids Clinical Trials Group 175 Team.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Double-Blind Method; Female; HIV Infections; Humans; Liver; Male; Nucleosides; Prospective Studies; Sex Characteristics; Zalcitabine; Zidovudine | 2000 |
Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Zalcitabine; Zidovudine | 2000 |
Therapeutic effects of nucleoside analogues on psychomotor slowing in HIV infection.
Topics: Adult; Anti-HIV Agents; Central Nervous System Diseases; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Middle Aged; Motor Skills; Stavudine; Zalcitabine; Zidovudine | 2001 |
Final CESARE trial results show continued clinical and survival benefit.
Topics: Acetamides; Acetophenones; Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; Controlled Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Survival Rate; Zalcitabine; Zidovudine | 1997 |
Major study shows AZT monotherapy inferior.
Topics: CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV; HIV Infections; Humans; Randomized Controlled Trials as Topic; Zalcitabine; Zidovudine | 1995 |
New double vs. triple antiviral combination study, CD4 200-500, no prior treatment.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Nevirapine; Pyridines; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1995 |
Antiretroviral combination treatment prolongs life in people with HIV/AIDS.
Topics: Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1996 |
CPCRA 007: preliminary results of combination antiretroviral study.
Topics: Antiviral Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Randomized Controlled Trials as Topic; Zalcitabine; Zidovudine | 1996 |
Evidence for prolonged clinical benefit from initial combination antiretroviral therapy: Delta extended follow-up.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; Humans; International Cooperation; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Survival Analysis; Treatment Outcome; Zalcitabine; Zidovudine | 2001 |
Impact of highly active antiretroviral therapy on cognitive processing in HIV infection: cross-sectional and longitudinal studies of event-related potentials.
Topics: Adult; AIDS Dementia Complex; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cross-Sectional Studies; Didanosine; Drug Therapy, Combination; Evoked Potentials; Female; Humans; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Treatment Outcome; Zalcitabine; Zidovudine | 2002 |
Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; DNA, Viral; HIV-1; Humans; Multivariate Analysis; Prognosis; RNA, Viral; Zalcitabine; Zidovudine | 2003 |
Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen received.
Topics: Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Predictive Value of Tests; Reverse Transcriptase Inhibitors; Selection, Genetic; Thymidine; Zalcitabine; Zidovudine | 2003 |
More on the treatment-tropism relationship: the impact of prior antiretroviral treatment on HIV coreceptor tropism among subjects entering AIDS clinical trials group 175.
Topics: Adult; Anti-Retroviral Agents; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Middle Aged; Receptors, CCR5; Receptors, CXCR4; Zalcitabine; Zidovudine | 2007 |
The risk of developing peripheral neuropathy induced by nucleoside reverse transcriptase inhibitors decreases over time: evidence from the Delta trial.
Topics: Adult; Anti-HIV Agents; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; Humans; Incidence; Male; Middle Aged; Peripheral Nervous System Diseases; Reverse Transcriptase Inhibitors; Risk Factors; Time Factors; Zalcitabine; Zidovudine | 2008 |
261 other study(ies) available for zalcitabine and didanosine
| Article | Year |
|---|---|
Potential anti-AIDS drugs. Lipophilic, adenosine deaminase-activated prodrugs.
Topics: Adenosine Deaminase; Antiviral Agents; Cells, Cultured; Chemical Phenomena; Chemistry; Chromatography, High Pressure Liquid; Dideoxynucleosides; HIV; Kinetics; Prodrugs; Structure-Activity Relationship | 1991 |
HIV-1 reverse transcriptase inhibitor design using artificial neural networks.
Topics: Algorithms; Cell Line; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Structure; Neural Networks, Computer; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; T-Lymphocytes; Zidovudine | 1994 |
Synthesis and anti-HIV-1 activity of a series of 1-alkoxy-5-alkyl-6-(arylthio)uracils.
Topics: Animals; Anti-HIV Agents; HIV Reverse Transcriptase; HIV-1; Liver; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Rats; Rats, Sprague-Dawley; Spectrophotometry, Infrared; Structure-Activity Relationship; Uracil | 1997 |
Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs.
Topics: Acyclovir; Animals; Anion Transport Proteins; Antiviral Agents; Carrier Proteins; Didanosine; In Vitro Techniques; Lamivudine; Oocytes; Rats; Stavudine; Transfection; Trifluridine; Xenopus laevis; Zalcitabine; Zidovudine | 2000 |
New saponins from the starfish Certonardoa semiregularis.
Topics: Animals; Antineoplastic Agents; Antiviral Agents; Artemia; HeLa Cells; Humans; Korea; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Saponins; Starfish; Stereoisomerism; Steroids | 2002 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Absence of a universal mechanism of mitochondrial toxicity by nucleoside analogs.
Topics: Animals; Antimetabolites; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Didanosine; DNA, Mitochondrial; Dose-Response Relationship, Drug; Humans; Lactates; Liver Neoplasms; Mitochondria; Myocytes, Cardiac; Rats; Superoxides; Zalcitabine; Zidovudine | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship | 2009 |
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
Topics: Anti-HIV Agents; Cell Line, Tumor; Cell Survival; Cells, Cultured; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Molecular Structure; Reverse Transcriptase Inhibitors | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Synthesis of enantiomerically pure D- and L-bicyclo[3.1.0]hexenyl carbanucleosides and their antiviral evaluation.
Topics: Anti-HIV Agents; Antiviral Agents; Bridged Bicyclo Compounds; Cell Line; DNA Viruses; Epichlorohydrin; Humans; Nucleosides; RNA Viruses; Stereoisomerism | 2011 |
Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
Topics: Acetamides; Anti-HIV Agents; Cell Line; HIV Infections; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Triazoles; Virus Replication | 2011 |
Efficient synthesis of 3H,3'H-spiro[benzofuran-2,1'-isobenzofuran]-3,3'-dione as novel skeletons specifically for influenza virus type B inhibition.
Topics: Antiviral Agents; Benzofurans; Dose-Response Relationship, Drug; Influenza B virus; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.
Topics: Binding Sites; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Protein Binding; Protein Structure, Tertiary; Pyrimidines; Pyrimidinones; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2013 |
Ionic derivatives of betulinic acid exhibit antiviral activity against herpes simplex virus type-2 (HSV-2), but not HIV-1 reverse transcriptase.
Topics: Acyclovir; Animals; Antiviral Agents; Betulinic Acid; Chlorocebus aethiops; Herpesvirus 2, Human; HIV Reverse Transcriptase; HIV-1; Humans; Pentacyclic Triterpenes; Triterpenes; Vero Cells; Virus Replication | 2015 |
Synthesis and antiproliferative evaluation of novel 2-(4H-1,2,4-triazole-3-ylthio)acetamide derivatives as inducers of apoptosis in cancer cells.
Topics: Acetamides; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Humans; Membrane Potential, Mitochondrial; Structure-Activity Relationship; Triazoles | 2016 |
Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
Topics: Anti-HIV Agents; Drug Stability; Esters; HIV-1; Humans; Inhibitory Concentration 50; Methane; Models, Molecular; Reverse Transcriptase Inhibitors | 2016 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine.
Topics: Acquired Immunodeficiency Syndrome; Base Sequence; Cell Line; Cloning, Molecular; Didanosine; Drug Resistance, Microbial; Genetic Variation; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Sequence Data; Mutation; Oligodeoxyribonucleotides; Polymerase Chain Reaction; Restriction Mapping; RNA-Directed DNA Polymerase; Zalcitabine; Zidovudine | 1992 |
Combination therapy for HIV infection: getting closer.
Topics: Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Zalcitabine; Zidovudine | 1992 |
Trial of three drugs for HIV-infected patients.
Topics: Clinical Trials as Topic; Didanosine; HIV Infections; Humans; Zalcitabine; Zidovudine | 1992 |
Sodium-dependent nucleoside transport in choroid plexus from rabbit. Evidence for a single transporter for purine and pyrimidine nucleosides.
Topics: Adenosine Triphosphate; Animals; Carrier Proteins; Choroid Plexus; Cytarabine; Didanosine; Membrane Proteins; Nucleoside Transport Proteins; Purine Nucleosides; Pyrimidine Nucleosides; Rabbits; Sodium; Substrate Specificity; Zalcitabine; Zidovudine | 1992 |
Different pattern of activity of inhibitors of the human immunodeficiency virus in lymphocytes and monocyte/macrophages.
Topics: Adenine; Antibodies, Viral; Antiviral Agents; Benzodiazepines; CD4 Antigens; Cytokines; Didanosine; Doxorubicin; Drug Interactions; HIV; HIV Infections; Humans; Imidazoles; Leukocytes, Mononuclear; Lymphocytes; Macrophages; Monocytes; Organ Specificity; Organophosphonates; Zalcitabine; Zidovudine | 1992 |
Treatment of HIV infection: the antiretroviral nucleoside analogues. Introduction.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Didanosine; Drug Evaluation; HIV Infections; HIV-1; Humans; Nucleosides; Zalcitabine; Zidovudine | 1992 |
Inhibition of HIV infection of resting peripheral blood lymphocytes by nucleosides.
Topics: Base Sequence; Cells, Cultured; Didanosine; DNA, Viral; HIV; Humans; Lymphocyte Activation; Molecular Sequence Data; Polymerase Chain Reaction; Proviruses; T-Lymphocytes; Virus Replication; Zalcitabine; Zidovudine | 1992 |
Antiviral nucleoside toxicity in canine bone marrow progenitor cells and its relationship to drug permeation.
Topics: Animals; Biological Transport, Active; Colony-Forming Units Assay; Didanosine; Dipyridamole; Dogs; Dose-Response Relationship, Drug; Erythrocytes; Female; Granulocytes; Hematopoietic Stem Cells; In Vitro Techniques; Macrophages; Zalcitabine; Zidovudine | 1992 |
The transfer of anti-human immunodeficiency virus nucleoside compounds by the term human placenta.
Topics: Antiviral Agents; Chromatography, High Pressure Liquid; Didanosine; Female; HIV Infections; Humans; Maternal-Fetal Exchange; Osmolar Concentration; Placenta; Pregnancy; Zalcitabine; Zidovudine | 1992 |
Structural analysis of 2',3'-dideoxyinosine, 2',3'-dideoxyadenosine, 2',3'-dideoxyguanosine and 2',3'-dideoxycytidine by 500-MHz 1H-NMR spectroscopy and ab-initio molecular orbital calculations.
Topics: Didanosine; Dideoxyadenosine; Dideoxynucleosides; Magnetic Resonance Spectroscopy; Models, Chemical; Molecular Structure; Spectrum Analysis; Structure-Activity Relationship; Temperature; Thermodynamics; Zalcitabine | 1992 |
Effect of six virustatic nucleoside analogues on the development of fetal rat thymus in organ culture.
Topics: Animals; Antiviral Agents; Cell Differentiation; Cell Division; Cells, Cultured; Didanosine; Female; Flow Cytometry; Ganciclovir; Immunity, Cellular; Male; Nucleotides; Organ Culture Techniques; Pregnancy; Rats; Rats, Wistar; Thymus Gland; Vidarabine; Zalcitabine; Zidovudine | 1992 |
Testing an anti-HIV trio.
Topics: Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Zalcitabine; Zidovudine | 1992 |
Effects of bone marrow stimulatory cytokines on human immunodeficiency virus replication and the antiviral activity of dideoxynucleosides in cultures of monocyte/macrophages.
Topics: Antiviral Agents; Bone Marrow; Cells, Cultured; Cytokines; Didanosine; Dideoxynucleosides; Erythropoietin; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; HIV; Humans; Macrophage Colony-Stimulating Factor; Macrophages; Monocytes; Virus Replication; Zalcitabine; Zidovudine | 1992 |
(-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro.
Topics: Cell Death; Cells, Cultured; Didanosine; Giant Cells; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Lamivudine; RNA-Directed DNA Polymerase; Tritium; Virus Replication; Zalcitabine; Zidovudine | 1992 |
The PC12 cell as a model for studies of the mechanism of induction of peripheral neuropathy by anti-HIV-1 dideoxynucleoside analogs.
Topics: Animals; Axons; Bone Marrow; Cell Division; Cell Line, Transformed; Didanosine; Dideoxynucleosides; Dose-Response Relationship, Drug; Peripheral Nervous System Diseases; Stavudine; Tumor Cells, Cultured; Zalcitabine; Zidovudine | 1991 |
Therapeutic options expand, take new directions.
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Humans; United States; Zalcitabine; Zidovudine | 1991 |
AIDS drug update: DDI and DDC.
Topics: Acquired Immunodeficiency Syndrome; Adult; Didanosine; Humans; Male; Patient Education as Topic; Zalcitabine | 1991 |
[Dideoxycytidine and dideoxyinosine: new therapy for acquired immunodeficiency syndrome?].
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Humans; Zalcitabine | 1991 |
Bacterial infections in human immunodeficiency virus type 1-infected children: the impact of central venous catheters and antiretroviral agents.
Topics: Adolescent; Antiviral Agents; Bacterial Infections; Catheterization, Central Venous; Child; Child, Preschool; Didanosine; Female; HIV Infections; HIV-1; Humans; Male; Retrospective Studies; Zalcitabine; Zidovudine | 1991 |
Modified tetrazolium-based colorimetric method for determining the activities of anti-HIV compounds.
Topics: Antiviral Agents; Cell Line; Colorimetry; Didanosine; Foscarnet; HIV-1; Humans; Phosphonoacetic Acid; Tetrazolium Salts; Thymidine; Zalcitabine; Zidovudine | 1991 |
Experimental studies of the hematologic and immune system toxicity of nucleoside derivatives used against HIV infection.
Topics: Animals; Bone Marrow; Didanosine; Dideoxyadenosine; Female; HIV Infections; Immune System; Immunoglobulin M; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Zalcitabine; Zidovudine | 1991 |
Pharmacokinetics of anti-HIV nucleosides in microswine.
Topics: Animals; Antiviral Agents; Chromatography, High Pressure Liquid; Didanosine; Half-Life; HIV; Male; Nucleosides; Swine; Swine, Miniature; Zalcitabine; Zidovudine | 1991 |
Strength in numbers. Researchers begin combining compounds to fight AIDS.
Topics: Acquired Immunodeficiency Syndrome; CD4 Antigens; Didanosine; Drug Therapy, Combination; Humans; Interferons; Zalcitabine; Zidovudine | 1990 |
[Inhibitors of HIV-1 reverse transcriptase and protease as chemotherapeutics for AIDS].
Topics: Acquired Immunodeficiency Syndrome; Animals; Antiviral Agents; Didanosine; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Reverse Transcriptase Inhibitors; Thymine; Zalcitabine; Zidovudine | 1991 |
[Combination therapies with anti-retroviral agents in HIV and AIDS infections].
Topics: Acquired Immunodeficiency Syndrome; Anti-Bacterial Agents; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Interferons; Zalcitabine; Zidovudine | 1991 |
US drug regulation. AIDS politics change rules.
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Humans; Legislation, Drug; United States; United States Food and Drug Administration; Zalcitabine | 1991 |
Exacerbation of dideoxycytidine-induced neuropathy with dideoxyinosine.
Topics: Adult; AIDS-Associated Nephropathy; Antiviral Agents; Didanosine; Drug Synergism; Drug Therapy, Combination; HIV Infections; Humans; Male; Peripheral Nervous System Diseases; Zalcitabine | 1991 |
The inhibitory activity of a peptide derivative against the growth of simian immunodeficiency virus in C8166 cells.
Topics: Animals; Antiviral Agents; Cell Line; Didanosine; HIV Protease; HIV Protease Inhibitors; Humans; Microscopy, Electron; Saquinavir; Simian Immunodeficiency Virus; Zalcitabine | 1991 |
Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity.
Topics: Antiviral Agents; Cell Line; Cytarabine; Didanosine; Dideoxynucleosides; DNA, Mitochondrial; HIV; Humans; Lymphocyte Activation; Nucleosides; Stavudine; T-Lymphocytes; Zalcitabine; Zidovudine | 1991 |
Determination of 3'-azido-3'-deoxythymidine, 2',3'-dideoxycytidine, 3'-fluoro-3'-deoxythymidine and 2',3'-dideoxyinosine in biological samples by high-performance liquid chromatography.
Topics: Animals; Antiviral Agents; Chromatography, High Pressure Liquid; Didanosine; Dideoxynucleosides; Humans; Liver; Rats; Zalcitabine; Zidovudine | 1990 |
Surrogate markers of disease studied as means of determining AIDS drugs' effectiveness.
Topics: Acquired Immunodeficiency Syndrome; CD4-Positive T-Lymphocytes; Didanosine; Humans; Leukocyte Count; Zalcitabine | 1990 |
Drugs for HIV infection.
Topics: Didanosine; HIV Infections; Humans; Zalcitabine; Zidovudine | 1990 |
Clinical trials of combination therapies for HIV infection. Rationale for development of multidrug therapy.
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Drug Therapy, Combination; Humans; Zalcitabine; Zidovudine | 1990 |
Testing of nucleoside analogues in cats infected with feline leukemia virus: a model.
Topics: Acquired Immunodeficiency Syndrome; Animals; Antibodies, Viral; Antiviral Agents; Cats; Cell Line; Didanosine; Dideoxyadenosine; Dideoxynucleosides; Disease Models, Animal; Drug Evaluation, Preclinical; Immunologic Deficiency Syndromes; Leukemia Virus, Feline; Leukemia, Experimental; Nucleosides; Specific Pathogen-Free Organisms; Virus Replication; Zalcitabine; Zidovudine | 1989 |
Determination of 2',3'-dideoxyadenosine, 2',3'-dideoxyinosine and 2',3'-dideoxycytidine in biological samples.
Topics: Animals; Antiviral Agents; Cats; Chromatography, High Pressure Liquid; Chromatography, Ion Exchange; Didanosine; Dideoxyadenosine; Dideoxynucleosides; Female; Half-Life; Injections, Intravenous; Mice; Mice, Inbred Strains; Rats; Rats, Inbred F344; Spectrophotometry, Ultraviolet; Zalcitabine | 1988 |
[Antiretroviral treatment against HIV].
Topics: Antiviral Agents; Didanosine; HIV Infections; Humans; Zalcitabine; Zidovudine | 1995 |
HIV-1, the brain, and combination therapy.
Topics: Adult; AIDS Dementia Complex; Antiviral Agents; Child; Didanosine; Drug Combinations; HIV-1; Humans; Lamivudine; Neuroprotective Agents; Stavudine; Zalcitabine; Zidovudine | 1995 |
Transmembrane P-glycoprotein (P-gp/P-170) in HIV infection: analysis of lymphocyte surface expression and drug-unrelated function.
Topics: Adult; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Didanosine; Female; HIV Seropositivity; Humans; Immunophenotyping; Interleukin-2; Lymphocyte Activation; Lymphocytes; Male; Phytohemagglutinins; Zalcitabine; Zidovudine | 1995 |
Placental transfer and fetal disposition of 2',3'-dideoxycytidine and 2',3'-dideoxyinosine in the rhesus monkey.
Topics: Animals; Antiviral Agents; Didanosine; Female; Fetus; Macaca mulatta; Maternal-Fetal Exchange; Phosphorylation; Pregnancy; Pregnancy, Animal; Tissue Distribution; Zalcitabine | 1995 |
Combined drugs may be better than zidovudine alone for immunocompromised adults infected with HIV-1.
Topics: Adult; Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Immunocompromised Host; Treatment Outcome; Zalcitabine; Zidovudine | 1995 |
[AIDS therapy with reverse transcriptase inhibitors].
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Drug Therapy, Combination; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 1993 |
Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.
Topics: Amino Acid Sequence; Base Sequence; Cloning, Molecular; Codon; Didanosine; DNA Primers; Drug Resistance, Microbial; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Molecular Sequence Data; Mutagenesis, Site-Directed; Mutation; RNA-Directed DNA Polymerase; Zalcitabine; Zidovudine | 1994 |
Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor.
Topics: Antiviral Agents; Benzodiazepines; Didanosine; Drug Synergism; Gene Products, tat; HeLa Cells; HIV; HIV Protease Inhibitors; Humans; Isoquinolines; Nevirapine; Pyridines; Pyrroles; Quinolines; Reverse Transcriptase Inhibitors; Saquinavir; tat Gene Products, Human Immunodeficiency Virus; Zalcitabine; Zidovudine | 1994 |
Anti-angiogenesis agent DS-4152 is a potent and selective inhibitor of HIV-1 replication in vitro.
Topics: Antiviral Agents; Cell Line; Didanosine; Giant Cells; HIV-1; Humans; Neovascularization, Pathologic; Polysaccharides, Bacterial; Virus Replication; Zalcitabine | 1994 |
[Anti-HIV-therapy. Monotherapy with drugs delaying the course of the disease has limited effect].
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Dose-Response Relationship, Drug; Drug Therapy, Combination; HIV Infections; Humans; Palliative Care; Zalcitabine; Zidovudine | 1994 |
The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2', 3'-dideoxycytidine, 2',3'-dideoxy-3'-thiacytidine, and 2',3'-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro.
Topics: Amino Acid Sequence; Antiviral Agents; Base Sequence; Cloning, Molecular; Didanosine; DNA Primers; Drug Resistance, Microbial; HIV Reverse Transcriptase; HIV-1; Kinetics; Lamivudine; Molecular Sequence Data; Mutagenesis, Site-Directed; Point Mutation; Polynucleotides; Recombinant Proteins; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Substrate Specificity; Templates, Genetic; Zalcitabine | 1994 |
The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds.
Topics: Antiviral Agents; Cells, Cultured; Cytotoxicity Tests, Immunologic; Didanosine; Drug Interactions; HIV Reverse Transcriptase; HIV-1; Humans; Indolizines; Isoquinolines; Leukocytes, Mononuclear; Molecular Structure; Nevirapine; Pyridines; Quinolines; Reverse Transcriptase Inhibitors; Saquinavir; Uracil; Zalcitabine; Zidovudine | 1995 |
Risk factors for dideoxynucleoside-induced toxic neuropathy in patients with the human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Antiviral Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Incidence; Male; Middle Aged; Peripheral Nervous System Diseases; Retrospective Studies; Risk Factors; Zalcitabine | 1995 |
In vitro comparison of selected triple-drug combinations for suppression of HIV-1 replication: the Inter-Company Collaboration Protocol.
Topics: Antiviral Agents; Cell Line, Transformed; Cytopathogenic Effect, Viral; Didanosine; Drug Synergism; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Isoquinolines; Lamivudine; Nevirapine; Pyridines; Quinolines; Reverse Transcriptase Inhibitors; Saquinavir; Virus Replication; Zalcitabine; Zidovudine | 1995 |
Other AIDS drug regimens beat AZT alone, reduce clinical progression and mortality.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Humans; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1995 |
Combination superior to zidovudine in Delta trial.
Topics: Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Zalcitabine; Zidovudine | 1995 |
Drugs for AIDS and associated infections.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Antiprotozoal Agents; Antiviral Agents; Atovaquone; Candidiasis, Oral; Clindamycin; Clotrimazole; Cryptosporidiosis; Cytomegalovirus Infections; Dapsone; Didanosine; Drug Combinations; Drug Therapy, Combination; Fluconazole; Flucytosine; Folic Acid Antagonists; Foscarnet; Glucuronates; Herpes Simplex; Herpes Zoster; Humans; Isoniazid; Itraconazole; Ketoconazole; Lamivudine; Mycobacterium avium-intracellulare Infection; Naphthoquinones; Nystatin; Pentamidine; Pneumocystis Infections; Pneumonia, Pneumocystis; Prednisone; Primaquine; Reverse Transcriptase Inhibitors; Stavudine; Syphilis; Toxoplasmosis; Trimetrexate; Tuberculosis; Zalcitabine; Zidovudine | 1995 |
AZT combination trial shows positive results.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Humans; Zalcitabine; Zidovudine | 1995 |
Confirmation for combination AIDS therapy.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Controlled Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Humans; Multicenter Studies as Topic; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1995 |
Study shows two drugs are best for HIV infection.
Topics: Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Zalcitabine; Zidovudine | 1995 |
Effect of zidovudine and didanosine treatment on heart function in children infected with human immunodeficiency virus.
Topics: Acquired Immunodeficiency Syndrome; Cardiomyopathies; CD4 Lymphocyte Count; Child, Preschool; Didanosine; Dose-Response Relationship, Drug; Echocardiography; Female; Heart; HIV; Humans; Infant; Infant, Newborn; Male; Medical Records; Retrospective Studies; Severity of Illness Index; Zalcitabine; Zidovudine | 1995 |
Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2',3'-dideoxynucleoside activities against replication of human immunodeficiency virus.
Topics: Adenosine Kinase; Cells, Cultured; Didanosine; DNA Replication; Drug Synergism; HIV-1; Humans; Hydroxyurea; Phosphorylation; Proviruses; Uridine Kinase; Virus Replication; Zalcitabine; Zidovudine | 1995 |
Identification of drug-related genotypic changes in HIV-1 from serum using the selective polymerase chain reaction.
Topics: Antiviral Agents; Base Sequence; Didanosine; DNA Primers; DNA, Viral; Efficiency; Evaluation Studies as Topic; Genes, pol; Genotype; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Molecular Sequence Data; Mutation; Polymerase Chain Reaction; Proviruses; Reproducibility of Results; RNA, Viral; Sensitivity and Specificity; Templates, Genetic; Virion; Zalcitabine; Zidovudine | 1994 |
Effects of the Th1 and Th2 stimulatory cytokines interleukin-12 and interleukin-4 on human immunodeficiency virus replication.
Topics: Antibodies, Monoclonal; Cells, Cultured; Cytopathogenic Effect, Viral; Didanosine; HIV Core Protein p24; HIV-1; Humans; Interleukin-12; Interleukin-4; Interleukins; Leukocytes, Mononuclear; Lymphocyte Activation; Macrophages; Monocytes; Muromonab-CD3; Phytohemagglutinins; T-Lymphocytes, Helper-Inducer; Virus Replication; Zalcitabine; Zidovudine | 1995 |
Quantitation of mitochondrial DNA in human lymphoblasts by a competitive polymerase chain reaction method: application to the study of inhibitors of mitochondrial DNA content.
Topics: Base Sequence; Blotting, Southern; Cell Division; Cells, Cultured; Didanosine; DNA, Mitochondrial; Humans; Lymphocytes; Molecular Sequence Data; Polymerase Chain Reaction; Zalcitabine | 1994 |
Didanosine-induced hypertriglyceridemia.
Topics: Acquired Immunodeficiency Syndrome; Adult; Didanosine; Humans; Hypertriglyceridemia; Male; Zalcitabine | 1995 |
Effects of dideoxyinosine and dideoxycytidine on the intracellular phosphorylation of zidovudine in human mononuclear cells.
Topics: Analysis of Variance; B-Lymphocytes; Cell Line; Cells, Cultured; Didanosine; Drug Interactions; Humans; Leukocytes, Mononuclear; Lymphocyte Activation; Phosphorylation; Phytohemagglutinins; Thymidine; Zalcitabine; Zidovudine | 1994 |
In-vitro activity of zidovudine, zalcitabine, and didanosine against mycoplasmas.
Topics: Didanosine; In Vitro Techniques; Microbial Sensitivity Tests; Mycoplasma; Zalcitabine; Zidovudine | 1993 |
Transfusion of blood components to persons infected with human immunodeficiency virus type 1: relationship to opportunistic infection.
Topics: AIDS-Related Opportunistic Infections; Blood Component Transfusion; Blood Group Antigens; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Cell Count; Cytomegalovirus Infections; Didanosine; Erythrocyte Transfusion; Female; HIV-1; Humans; Isoantibodies; Male; Mycobacterium avium-intracellulare Infection; Retrospective Studies; Risk Factors; Zalcitabine; Zidovudine | 1994 |
Antiretroviral therapy in HIV-infected adults. Which regimens are recommended?
Topics: Adult; CD4-Positive T-Lymphocytes; Didanosine; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; HIV Infections; Humans; Leukocyte Count; Zalcitabine; Zidovudine | 1994 |
Suppression of HIV production in resting lymphocytes by combining didanosine and hydroxamate compounds.
Topics: Cell Division; Cytopathogenic Effect, Viral; Didanosine; Drug Synergism; HIV-1; Humans; Interphase; Lymphocytes; Virus Replication; Zalcitabine; Zidovudine | 1994 |
Lower socioeconomic status and shorter survival following HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Adult; British Columbia; CD4 Lymphocyte Count; Cohort Studies; Didanosine; Health Services; HIV Infections; HIV Seropositivity; Homosexuality, Male; Humans; Income; Male; Pneumonia, Pneumocystis; Regression Analysis; Socioeconomic Factors; Survival Rate; Zalcitabine; Zidovudine | 1994 |
[HIV infection--current possibilities in antiviral therapy].
Topics: Antiviral Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Pancreatitis; Zalcitabine; Zidovudine | 1994 |
Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2',3'-dideoxynucleosides.
Topics: Antiviral Agents; Cells, Cultured; Didanosine; Dideoxynucleosides; Drug Synergism; HIV-1; Humans; Hydroxyurea; Virus Replication; Zalcitabine; Zidovudine | 1994 |
Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2',3'-dideoxyinosine in infected resting human lymphocytes.
Topics: Antiviral Agents; Asparagine; Aspartic Acid; Cell Survival; Cells, Cultured; Didanosine; Drug Synergism; HIV Infections; Humans; Hydroxyurea; In Vitro Techniques; Lymphocyte Activation; Lymphocytes; Virus Replication; Zalcitabine; Zidovudine | 1994 |
Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides.
Topics: Cell Survival; Cells, Cultured; Didanosine; DNA, Mitochondrial; Humans; Mitochondria; Stavudine; Zalcitabine | 1994 |
Generation of multiple drug resistance by sequential in vitro passage of the human immunodeficiency virus type 1.
Topics: Antiviral Agents; Cell Line; Cloning, Molecular; Didanosine; Drug Interactions; Drug Resistance, Microbial; HIV-1; Humans; Interferon-alpha; Neutralization Tests; Phenotype; Serial Passage; Stavudine; Zalcitabine; Zidovudine | 1994 |
[The anti-viral agents used in the treatment of AIDS].
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Humans; Zalcitabine; Zidovudine | 1994 |
Multiple-drug-resistant mutants of feline immunodeficiency virus selected with 2',3'-dideoxyinosine alone and in combination with 3'-azido-3'-deoxythymidine.
Topics: Animals; Antiviral Agents; Cats; Cells, Cultured; Didanosine; Drug Resistance, Microbial; Foscarnet; Immunodeficiency Virus, Feline; Mutation; Phenotype; Zalcitabine; Zidovudine | 1994 |
In vitro susceptibility of clinical isolates of HIV-1 to XM323, a non-peptidyl HIV protease inhibitor.
Topics: Antiviral Agents; Azepines; Cells, Cultured; Didanosine; Giant Cells; HIV Protease Inhibitors; HIV-1; Humans; Microbial Sensitivity Tests; Species Specificity; Zalcitabine; Zidovudine | 1994 |
What to do when zidovudine fails.
Topics: Didanosine; HIV Infections; Humans; Zalcitabine; Zidovudine | 1994 |
Prophylactic zalcitabine and interferon-alpha for a large-bore needlestick exposure to human immunodeficiency virus.
Topics: Adult; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV; HIV Infections; Humans; Infectious Disease Transmission, Patient-to-Professional; Interferon alpha-2; Interferon-alpha; Needlestick Injuries; Recombinant Proteins; Zalcitabine; Zidovudine | 1994 |
Intermittent therapy.
Topics: Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Zalcitabine; Zidovudine | 1994 |
Pharmacotherapy of HIV. APhA Editorial Board on Pharmaceutical Care for Patients with HIV Infection.
Topics: Adult; CD4 Antigens; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Male; Pharmaceutical Services; Zalcitabine; Zidovudine | 1994 |
Comparative embryonic cytotoxicity of antiretroviral nucleosides.
Topics: Animals; Antiviral Agents; Culture Techniques; Didanosine; Embryo, Mammalian; HIV; Mice; Nucleosides; Stavudine; Zalcitabine; Zidovudine | 1994 |
The drugs 2',3'-dideoxyinosine (ddI) and 2',3'-dideoxycytidine (ddC) are safe alternatives in people with AIDS with zidovudine-induced myopathy.
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Humans; Male; Muscular Diseases; Zalcitabine; Zidovudine | 1994 |
Decreased anti-human immunodeficiency virus type-1 activities of 2',3'-dideoxynucleoside analogs in MOLT-4 cell sublines resistant to 2',3'-dideoxynucleoside analogs.
Topics: Cell Line; Culture Media; Didanosine; Dideoxynucleosides; Drug Resistance, Microbial; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Microscopy, Electron; Time Factors; Zalcitabine; Zidovudine | 1993 |
Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; Didanosine; Drug Resistance, Microbial; HIV Seropositivity; HIV-1; Humans; Leukocytes, Mononuclear; Microbial Sensitivity Tests; Time Factors; Zalcitabine; Zidovudine | 1994 |
Human immunodeficiency virus type 1 pol gene mutations in an AIDS patient treated with multiple antiretroviral drugs.
Topics: Acquired Immunodeficiency Syndrome; Amino Acid Sequence; Base Sequence; Consensus Sequence; Didanosine; Genes, pol; Genotype; HIV-1; Humans; Leukocytes, Mononuclear; Molecular Sequence Data; Mutagenesis, Site-Directed; Mutation; Point Mutation; Polymerase Chain Reaction; Sequence Homology, Amino Acid; Time Factors; Viral Plaque Assay; Zalcitabine; Zidovudine | 1993 |
Regulation of megakaryocyte colony forming cell numbers and ploidy by dideoxynucleosides in immunodeficient mice.
Topics: Animals; Bone Marrow; Colony-Forming Units Assay; Didanosine; Female; Hematocrit; Hematopoietic Stem Cells; Leukemia Virus, Murine; Megakaryocytes; Mice; Mice, Inbred C57BL; Murine Acquired Immunodeficiency Syndrome; Platelet Count; Ploidies; Spleen; Zalcitabine; Zidovudine | 1993 |
[Treatment by antiviral drugs of HIV-infected patients].
Topics: Acyclovir; Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Interferon-alpha; Zalcitabine; Zidovudine | 1993 |
Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study.
Topics: Acquired Immunodeficiency Syndrome; Amino Acid Sequence; Base Sequence; Didanosine; Dose-Response Relationship, Drug; Genetic Variation; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Sequence Homology, Amino Acid; Zalcitabine; Zidovudine | 1993 |
Population-based estimates of antiretroviral therapy and anti-Pneumocystis prophylaxis in San Francisco: 1991.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antiviral Agents; Cohort Studies; Dapsone; Didanosine; Drug Combinations; Follow-Up Studies; HIV Infections; Humans; Male; Pentamidine; Pneumonia, Pneumocystis; San Francisco; Sulfamethizole; Trimethoprim; Zalcitabine; Zidovudine | 1993 |
Antiretroviral therapy.
Topics: Didanosine; Dideoxynucleosides; HIV Infections; Humans; Zalcitabine; Zidovudine | 1993 |
Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells.
Topics: 5'-Nucleotidase; Acquired Immunodeficiency Syndrome; Adenosine Kinase; AIDS-Related Complex; Chromatography, High Pressure Liquid; Deoxycytidine Kinase; Deoxyribonucleotides; Didanosine; HIV-1; Humans; Kinetics; Microbial Sensitivity Tests; Monocytes; Phosphorylation; Thymidine Kinase; Uridine Kinase; Zalcitabine; Zidovudine | 1993 |
Mechanism of action of N-butyl deoxynojirimycin in inhibiting HIV-1 infection and activity in combination with nucleoside analogs.
Topics: 1-Deoxynojirimycin; Antiviral Agents; CD4 Antigens; Cell Line; Didanosine; Drug Interactions; HIV Envelope Protein gp120; HIV-1; Humans; Nucleosides; Zalcitabine; Zidovudine | 1993 |
High-level resistance to zidovudine but not to zalcitabine or didanosine in human immunodeficiency virus from children receiving antiretroviral therapy.
Topics: Acquired Immunodeficiency Syndrome; Child; Child, Preschool; Didanosine; DNA, Viral; Drug Resistance, Microbial; Drug Therapy, Combination; HIV-1; Humans; Infant; Microbial Sensitivity Tests; Mutation; Polymerase Chain Reaction; Time Factors; Zalcitabine; Zidovudine | 1993 |
The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine.
Topics: Antiviral Agents; Base Sequence; Cloning, Molecular; Didanosine; Drug Resistance, Microbial; HIV-1; Humans; Lamivudine; Methionine; Mutagenesis, Site-Directed; Mutation; Stereoisomerism; Valine; Zalcitabine | 1993 |
Antiretroviral therapy and medical management of the human immunodeficiency virus-infected child. Working Group on Antiretroviral Therapy: National Pediatric HIV Resource Center.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Child; Child, Preschool; Didanosine; HIV Infections; Humans; Immunoglobulins, Intravenous; Infant; Zalcitabine; Zidovudine | 1993 |
A pilot study of sequential therapy with zidovudine plus acyclovir, dideoxyinosine, and dideoxycytidine in patients with severe human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; AIDS-Related Complex; Antigens, CD; Biomarkers; Body Weight; CD4 Antigens; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; HIV Core Protein p24; Humans; Male; Middle Aged; Pilot Projects; T-Lymphocyte Subsets; Time Factors; Zalcitabine; Zidovudine | 1993 |
Preliminary study analysis suggests similar efficacy for didanosine and zalcitabine.
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Humans; Treatment Outcome; Zalcitabine; Zidovudine | 1993 |
Transdermal delivery of dideoxynucleoside-type anti-HIV drugs. 1. Stability studies for hairless rat skin permeation.
Topics: Administration, Cutaneous; Animals; Anti-Infective Agents, Local; Antiviral Agents; Chromatography, High Pressure Liquid; Didanosine; Dideoxynucleosides; Enzyme Inhibitors; Female; Half-Life; HIV-1; In Vitro Techniques; Rats; Rats, Nude; Skin Absorption; Zalcitabine; Zidovudine | 1995 |
Effects of 3'-deoxynucleoside 5'-triphosphate concentrations on chain termination by nucleoside analogs during human immunodeficiency virus type 1 reverse transcription of minus-strand strong-stop DNA.
Topics: Antiviral Agents; Base Sequence; Cells, Cultured; Didanosine; Dideoxynucleotides; DNA, Viral; HIV-1; Humans; Lamivudine; Molecular Sequence Data; Nucleic Acid Conformation; Nucleosides; Nucleotides; Phytohemagglutinins; RNA, Viral; Thymine Nucleotides; Transcription, Genetic; Zalcitabine; Zidovudine | 1996 |
[Combination therapy of HIV].
Topics: Antimetabolites; Antiviral Agents; Denmark; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Male; Reverse Transcriptase Inhibitors; Zalcitabine | 1996 |
Inhibitory effect of 3'-azido-3'-deoxythymidine on proliferative responsiveness of CD8+ lymphocytes to interleukin-2.
Topics: Antiviral Agents; CD8-Positive T-Lymphocytes; Cell Division; Didanosine; Humans; Interleukin-2; Lamivudine; Lymphocyte Activation; Zalcitabine; Zidovudine | 1994 |
Recognition of the highly conserved YMDD region in the human immunodeficiency virus type 1 reverse transcriptase by HLA-A2-restricted cytotoxic T lymphocytes from an asymptomatic long-term nonprogressor.
Topics: Amino Acid Sequence; Antiviral Agents; Base Sequence; Conserved Sequence; Deoxycytidine; Didanosine; DNA Primers; Drug Resistance, Microbial; Epitopes; HIV Infections; HIV Reverse Transcriptase; HIV-1; HLA-A2 Antigen; Humans; Lamivudine; Molecular Sequence Data; Oligopeptides; Polymerase Chain Reaction; RNA-Directed DNA Polymerase; T-Lymphocytes, Cytotoxic; Zalcitabine | 1996 |
Managing HIV disease after Delta.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Didanosine; Drug Combinations; HIV Infections; Humans; Randomized Controlled Trials as Topic; Zalcitabine; Zidovudine | 1996 |
The mutation frequency of feline immunodeficiency virus enhanced by 3'-azido-3'-deoxythymidine.
Topics: Animals; Antiviral Agents; Bromodeoxyuridine; Cats; Cell Line; Didanosine; Dose-Response Relationship, Drug; Gene Frequency; Immunodeficiency Virus, Feline; Kidney; Mutation; Virus Cultivation; Zalcitabine; Zidovudine | 1996 |
Factors associated with changes in the use of antiretroviral therapy by a cohort of homosexual men infected with human immunodeficiency virus type 1.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Cohort Studies; Didanosine; Drug Therapy, Combination; Drug Utilization; Follow-Up Studies; Hemoglobins; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Multicenter Studies as Topic; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 1995 |
Transdermal delivery of dideoxynucleoside-type anti-HIV drugs. 2. The effect of vehicle and enhancer on skin permeation.
Topics: Animals; Antiviral Agents; Didanosine; Drug Delivery Systems; Female; Rats; Skin; Zalcitabine; Zidovudine | 1996 |
Adverse events from drug therapy for human immunodeficiency virus disease.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Dapsone; Didanosine; Female; HIV Infections; Humans; Male; Pneumonia, Pneumocystis; Risk Factors; Trimethoprim, Sulfamethoxazole Drug Combination; Urban Health; Zalcitabine; Zidovudine | 1996 |
[Anti-retroviral monotherapy with nucleoside analogues].
Topics: Antiviral Agents; Didanosine; HIV Infections; Humans; Zalcitabine; Zidovudine | 1995 |
Human immunodeficiency virus type 1 kinetics in lymph nodes compared with plasma.
Topics: Antiviral Agents; Biopsy; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Kinetics; Lamivudine; Lymph Nodes; RNA, Viral; Viremia; Zalcitabine; Zidovudine | 1996 |
The data and safety monitoring board and acquired immune deficiency syndrome (AIDS) clinical trials.
Topics: Advisory Committees; Anti-Infective Agents; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Confidentiality; Conflict of Interest; Didanosine; Drug Evaluation; Federal Government; HIV Infections; Humans; National Institutes of Health (U.S.); Organizational Objectives; Professional Staff Committees; Pyrimethamine; Reverse Transcriptase Inhibitors; Risk Assessment; Toxoplasmosis, Cerebral; Treatment Outcome; United States; Zalcitabine; Zidovudine | 1995 |
Synergistic inhibition of human immunodeficiency virus isolates (including 3'-azido-3'-deoxythymidine-resistant isolates) by foscarnet in combination with 2',3'-dideoxyinosine or 2',3'-dideoxycytidine.
Topics: Antiviral Agents; Cells, Cultured; Didanosine; Drug Combinations; Drug Resistance, Microbial; Drug Synergism; Foscarnet; HIV-1; Humans; Microbial Sensitivity Tests; Monocytes; Zalcitabine; Zidovudine | 1996 |
Combination antiretroviral chemotherapy: a potential strategy in AIDS-related malignancy.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cell Division; Didanosine; HIV Infections; HL-60 Cells; Humans; Zalcitabine; Zidovudine | 1996 |
Combination drug treatment benefits patients with HIV.
Topics: Antiviral Agents; Didanosine; Drug Combinations; HIV Infections; Humans; Zalcitabine; Zidovudine | 1996 |
[Prescription of antiretroviral and prophylactic drugs in HIV diseases: reality of medical practices].
Topics: Anti-Infective Agents; Antiviral Agents; CD4 Lymphocyte Count; Dapsone; Didanosine; Drug Utilization; France; HIV Infections; Hospital Information Systems; Hospital Records; Humans; Pentamidine; Trimethoprim, Sulfamethoxazole Drug Combination; Zalcitabine; Zidovudine | 1995 |
Therapy of HIV infections: problems and prospects.
Topics: Anti-HIV Agents; Didanosine; Drug Resistance, Microbial; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Stavudine; Urban Health; Zalcitabine; Zidovudine | 1996 |
Therapy for human immunodeficiency virus infection -- what have we learned?
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Zalcitabine; Zidovudine | 1996 |
Selection and characterization of a mutant of feline immunodeficiency virus resistant to 2',3'-dideoxycytidine.
Topics: Amino Acid Sequence; Animals; Antiviral Agents; Base Sequence; Cats; Cell Line; Didanosine; Drug Resistance, Microbial; Immunodeficiency Virus, Feline; Molecular Sequence Data; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Zalcitabine; Zidovudine | 1996 |
Inhibition of the in vitro infectivity and cytopathic effect of human foamy virus by dideoxynucleosides.
Topics: Blotting, Southern; Cytopathogenic Effect, Viral; Didanosine; Dideoxynucleosides; DNA, Viral; Humans; Microscopy, Electron; Spumavirus; Tumor Cells, Cultured; Zalcitabine; Zidovudine | 1996 |
Differential cytopathicity and susceptibility of Ghanaian highly divergent HIV-2 -GH2-, prototype HIV-2 -GH1-, and prototype HIV-1 -GH3- to inhibition by ddCyd and ddIno.
Topics: Antiviral Agents; Cytopathogenic Effect, Viral; Didanosine; Drug Evaluation, Preclinical; Ghana; HIV-1; HIV-2; Humans; Microbial Sensitivity Tests; Virus Cultivation; Zalcitabine | 1995 |
Stavudine selectively induces apoptosis in HIV type 1-infected cells.
Topics: Anti-HIV Agents; Apoptosis; Cell Line; Didanosine; DNA Fragmentation; Down-Regulation; HIV Reverse Transcriptase; HIV-1; Humans; Nevirapine; Proto-Oncogene Proteins c-bcl-2; Pyridines; Reverse Transcriptase Inhibitors; Stavudine; T-Lymphocytes; Thymidine; Zalcitabine; Zidovudine | 1997 |
The Delta trial.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Zalcitabine; Zidovudine | 1997 |
Treatment of late-state HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Double-Blind Method; Drug Combinations; HIV Infections; Humans; Randomized Controlled Trials as Topic; Reproducibility of Results; Reverse Transcriptase Inhibitors; Treatment Outcome; Zalcitabine; Zidovudine | 1997 |
The impact of ethanol and Marinol/marijuana usage on HIV+/AIDS patients undergoing azidothymidine, azidothymidine/dideoxycytidine, or dideoxyinosine therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Alcohol Drinking; Amylases; Anti-HIV Agents; Appetite Stimulants; CD4 Lymphocyte Count; Didanosine; Dronabinol; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Seropositivity; Humans; Liver Function Tests; Male; Marijuana Smoking; Middle Aged; Pancreatitis, Alcoholic; Zalcitabine; Zidovudine | 1997 |
Effect of nucleoside analogs on neurite regeneration and mitochondrial DNA synthesis in PC-12 cells.
Topics: Animals; Didanosine; Dideoxynucleosides; DNA Replication; DNA, Mitochondrial; Nerve Growth Factors; Neurites; PC12 Cells; Phosphorylation; Rats; Stavudine; Zalcitabine; Zidovudine | 1997 |
Treatment options for human immunodeficiency virus.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Child; Didanosine; Drug Approval; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant, Newborn; Lamivudine; Male; Saquinavir; Stavudine; United States; United States Food and Drug Administration; Zalcitabine; Zidovudine | 1996 |
[Therapeutic strategies against HIV: status in 1994 and future prospectives].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Forecasting; HIV Infections; Humans; Male; Zalcitabine; Zidovudine | 1994 |
Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells.
Topics: Anti-HIV Agents; Biopsy; Cell Differentiation; Cell Division; Cells, Cultured; Didanosine; DNA, Mitochondrial; Dose-Response Relationship, Drug; Electron Transport Complex II; Electron Transport Complex IV; Humans; Kinetics; Lactates; Lipid Metabolism; Mitochondria, Muscle; Multienzyme Complexes; Muscle, Skeletal; NAD(P)H Dehydrogenase (Quinone); Nucleic Acid Synthesis Inhibitors; Oxidoreductases; Succinate Dehydrogenase; Zalcitabine; Zidovudine | 1997 |
Correlation between plasma HIV-1 RNA levels and the rate of immunologic decline.
Topics: Anti-HIV Agents; beta 2-Microglobulin; CD4 Lymphocyte Count; Didanosine; Disease Progression; DNA, Viral; Drug Therapy, Combination; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Longitudinal Studies; RNA, Viral; Stavudine; Viral Load; Viremia; Virus Replication; Zalcitabine; Zidovudine | 1997 |
Downregulation of increased CD95 (APO-1/Fas) ligand in T cells from human immunodeficiency virus-type 1-infected children after antiretroviral therapy.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child; Didanosine; Drug Therapy, Combination; Fas Ligand Protein; fas Receptor; Gene Expression Regulation; HIV Infections; HIV-1; Humans; Lamivudine; Membrane Glycoproteins; Reverse Transcriptase Inhibitors; RNA, Messenger; T-Lymphocytes; Time Factors; Transcription, Genetic; Zalcitabine; Zidovudine | 1997 |
Cure or control of HIV/AIDS?
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; Humans; Indinavir; Lamivudine; Models, Biological; Nevirapine; Pyridines; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1997 |
[Anti-retrovirals].
Topics: Anti-HIV Agents; Didanosine; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 1997 |
Lamivudine (3TC) phosphorylation and drug interactions in vitro.
Topics: Anti-HIV Agents; Cells, Cultured; Deoxycytidine; Didanosine; Dideoxynucleosides; Drug Interactions; Humans; Kinetics; Lamivudine; Lymphocyte Activation; Lymphocytes; Mitogens; Models, Chemical; Monocytes; Phosphorylation; Stavudine; Tumor Cells, Cultured; Zalcitabine; Zidovudine | 1997 |
[Initial administration of a protease inhibitor delays the progression of AIDS by half time].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; Disease Progression; HIV Infections; HIV Protease Inhibitors; Humans; Time Factors; Zalcitabine; Zidovudine | 1997 |
Drugs for HIV infection.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Delavirdine; Diarrhea; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Virus Replication; Zalcitabine; Zidovudine | 1997 |
HIV-1 acquires resistance to two classes of antiviral drugs through homologous recombination.
Topics: Animals; Anti-HIV Agents; Cell Line, Transformed; COS Cells; Didanosine; Drug Resistance, Microbial; Drug Resistance, Multiple; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Mutagenesis; Oligopeptides; Polymerase Chain Reaction; Recombination, Genetic; Reverse Transcriptase Inhibitors; Transfection; Virus Replication; Zalcitabine; Zidovudine | 1997 |
Effect of protease inhibitors on nucleoside analogue phosphorylation in vitro.
Topics: Anti-HIV Agents; Cell Count; Cell Survival; Didanosine; Drug Interactions; Humans; Indinavir; Lamivudine; Leukocytes, Mononuclear; Nucleosides; Phosphorylation; Protease Inhibitors; Ritonavir; Saquinavir; Stavudine; Trypan Blue; Tumor Cells, Cultured; Zalcitabine; Zidovudine | 1998 |
Survival in 2367 zidovudine-treated patients according to use of other nucleoside analogue drugs. The EuroSIDA Study Group.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Didanosine; Dideoxynucleosides; Disease Progression; Drug Therapy, Combination; Europe; Female; Follow-Up Studies; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Stavudine; Survival Analysis; Zalcitabine; Zidovudine | 1998 |
Combination therapy for HIV: the effect on inpatient activity, morbidity and mortality of a cohort of patients.
Topics: Anti-HIV Agents; Cohort Studies; Cost Savings; Costs and Cost Analysis; Didanosine; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; Humans; Prospective Studies; Zalcitabine; Zidovudine | 1998 |
Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance.
Topics: Animals; Anti-HIV Agents; Cells, Cultured; COS Cells; Didanosine; Dideoxynucleosides; Drug Resistance, Microbial; Drug Resistance, Multiple; Evolution, Molecular; Genes, pol; HIV-1; Humans; Lymphocytes; Microbial Sensitivity Tests; Mutation; Virus Replication; Zalcitabine; Zidovudine | 1998 |
Emergence of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Didanosine; Dideoxynucleosides; Disease Progression; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Genetic Variation; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Point Mutation; Reverse Transcriptase Inhibitors; RNA, Viral; Zalcitabine; Zidovudine | 1998 |
Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Female; Herpesvirus 8, Human; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sarcoma, Kaposi; Stavudine; Treatment Outcome; Viral Load; Viremia; Zalcitabine; Zidovudine | 1998 |
The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
Topics: Anti-HIV Agents; Cohort Studies; Didanosine; Dideoxynucleosides; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Methionine; Point Mutation; Reverse Transcriptase Inhibitors; Stavudine; Valine; Zalcitabine; Zidovudine | 1998 |
A mixed model for repeated dilution assays.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV; HIV Infections; Humans; Models, Statistical; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Reproducibility of Results; Viral Load; Zalcitabine; Zidovudine | 1998 |
Metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro.
Topics: Anti-HIV Agents; Cell Line; Deamination; Deoxycytidine Kinase; Didanosine; DNA Polymerase gamma; DNA-Directed DNA Polymerase; DNA, Mitochondrial; DNA, Viral; Drug Interactions; HIV Reverse Transcriptase; HIV-1; Phosphorylation; Stavudine; Virus Replication; Zalcitabine; Zidovudine | 1998 |
Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
Topics: Adult; Anti-HIV Agents; Cross-Sectional Studies; Didanosine; Dideoxynucleosides; Drug Resistance, Microbial; Female; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Prevalence; Reverse Transcriptase Inhibitors; Spain; Zalcitabine; Zidovudine | 1998 |
Risk of HIV dementia and opportunistic brain disease in AIDS and zidovudine therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS Dementia Complex; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Brain Diseases; Didanosine; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; Retrospective Studies; Risk; Stavudine; Treatment Outcome; Zalcitabine; Zidovudine | 1998 |
Comparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutations.
Topics: Anti-HIV Agents; Codon; Didanosine; DNA Probes; Drug Resistance, Microbial; Drug Therapy, Combination; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Polymerase Chain Reaction; Sequence Analysis, DNA; Zalcitabine; Zidovudine | 1998 |
Analysis of antiretroviral nucleosides by electrospray ionization mass spectrometry and collision induced dissociation.
Topics: Anti-HIV Agents; Didanosine; Dideoxynucleosides; Gas Chromatography-Mass Spectrometry; Lamivudine; Models, Chemical; Reverse Transcriptase Inhibitors; Spectrometry, Mass, Secondary Ion; Zalcitabine; Zidovudine | 1998 |
The sequential occurrence of pol 215 and pol 41 zidovudine resistance mutations is associated in an additive fashion with low CD4 cell counts and high plasma and cellular HIV viral load.
Topics: Adult; Anti-HIV Agents; Biomarkers; CD4 Lymphocyte Count; Cross-Sectional Studies; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV-1; Humans; Longitudinal Studies; Male; Mutation; RNA, Viral; Viral Load; Zalcitabine; Zidovudine | 1998 |
[Weak antiviral effect of changing two nucleoside analogues combined with antiretroviral agents. 3TC and d4T after ZDU and ddi or ddc].
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Retrospective Studies; Stavudine; Viral Load; Zalcitabine; Zidovudine | 1998 |
A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors.
Topics: Amino Acid Sequence; Anti-HIV Agents; Base Sequence; Cells, Cultured; Didanosine; Drug Resistance, Multiple; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutagenesis, Site-Directed; Mutation; Nucleosides; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1998 |
Zidovudine toxicity in uninfected healthcare workers. Italian Registry of Antiretroviral Prophylaxis.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Health Personnel; HIV Infections; Humans; Italy; Occupational Exposure; Registries; Retrospective Studies; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1997 |
Normal T-cell telomerase activity and upregulation in human immunodeficiency virus-1 infection.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cohort Studies; Didanosine; Drug Therapy, Combination; Enzyme Induction; HIV Infections; HIV-1; Humans; Lymphoid Tissue; Reverse Transcriptase Inhibitors; Telomerase; Telomere; Up-Regulation; Zalcitabine; Zidovudine | 1999 |
Antiretroviral drugs: new agents, new combinations line up against HIV.
Topics: Antiviral Agents; Australia; Didanosine; Drug Therapy, Combination; Europe; HIV; HIV Infections; Humans; Lamivudine; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ritonavir; Thiazoles; United States; Valine; Zalcitabine; Zidovudine | 1996 |
Patients with HIV-1 RNA below 1000 copies/ml after 48 weeks on dual nucleoside combination therapy. Delta Coordinating Committee.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Zalcitabine; Zidovudine | 1999 |
Data and safety monitoring in the Delta trial.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; Double-Blind Method; Drug Therapy, Combination; Humans; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Survival Analysis; Zalcitabine; Zidovudine | 1999 |
Relevance of AIDS treatment with two nucleoside analogues alone.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Humans; Survival Rate; Zalcitabine; Zidovudine | 1999 |
Changing cost of English HIV service provision 1996-1997. NPMS Steering Group. National Prospective Monitoring System.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Costs; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Hospital Costs; Humans; Nevirapine; RNA-Directed DNA Polymerase; United Kingdom; Zalcitabine; Zidovudine | 1999 |
Reaction times are faster in HIV-seropositive patients on antiretroviral therapy: A preliminary report.
Topics: Adult; Anti-HIV Agents; Case-Control Studies; CD4 Lymphocyte Count; CD4-CD8 Ratio; Choice Behavior; Cognition; Cross-Sectional Studies; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Pilot Projects; Psychiatric Status Rating Scales; Psychomotor Performance; Reaction Time; Statistics, Nonparametric; Zalcitabine; Zidovudine | 1999 |
Highly active anti-retroviral therapy (HAART) is associated with a lower level of CD4+ T cell apoptosis in HIV-infected patients.
Topics: Adult; Aged; Anti-HIV Agents; Apoptosis; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Stavudine; Viral Load; Zalcitabine; Zidovudine | 1999 |
Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
Topics: Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Didanosine; Disease Progression; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Incidence; Indinavir; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Risk Factors; Ritonavir; RNA, Viral; Salvage Therapy; Saquinavir; Stavudine; Switzerland; Treatment Failure; Viral Load; Zalcitabine; Zidovudine | 1999 |
Presence of genotypic resistance in nucleoside analogue-treated HIV-1-infected patients with undetectable viral load.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; Drug Resistance; Genes, pol; Genotype; HIV-1; Humans; Lamivudine; Point Mutation; RNA, Viral; Zalcitabine; Zidovudine | 1999 |
Different outcome in the first two patients with an HIV-1 multinucleoside drug-resistant T69SSS insertion in Spain.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Didanosine; Drug Resistance, Multiple; HIV Reverse Transcriptase; HIV-1; Humans; Male; Mutation; Spain; Zalcitabine; Zidovudine | 1999 |
Drugs for HIV infection.
Topics: Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Costs; Drug Therapy, Combination; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 2000 |
HIV-associated bacteremia: how it has changed in the highly active antiretroviral therapy (HAART) era.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Bacteremia; Community-Acquired Infections; Cross Infection; Didanosine; Drug Therapy, Combination; Female; Humans; Incidence; Male; Prospective Studies; Risk Factors; Viral Load; Zalcitabine; Zidovudine | 2000 |
Autonomic neuropathy in patients with HIV: course, impact of disease stage, and medication.
Topics: Adult; Aged; Anti-HIV Agents; Autonomic Nervous System Diseases; Brain Diseases; Cardiovascular System; Didanosine; Female; Follow-Up Studies; HIV Infections; Humans; Iris Diseases; Male; Middle Aged; Movement; Prevalence; Sensation; Stavudine; Zalcitabine | 2000 |
Baseline HIV type 1 genotypic resistance to a newly added nucleoside analog is predictive of virologic failure of the new therapy.
Topics: CD4 Lymphocyte Count; Didanosine; Drug Resistance, Microbial; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Polymerase Chain Reaction; Predictive Value of Tests; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Zalcitabine; Zidovudine | 2000 |
A novel genotype encoding a single amino acid insertion and five other substitutions between residues 64 and 74 of the HIV-1 reverse transcriptase confers high-level cross-resistance to nucleoside reverse transcriptase inhibitors. Abacavir CNA2007 Interna
Topics: Amino Acid Substitution; Codon; Cohort Studies; Didanosine; Drug Resistance, Microbial; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Phenotype; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Zalcitabine | 1999 |
Cutaneous side effects induced by indinavir.
Topics: Adult; Alopecia; Didanosine; Drug Eruptions; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Lipodystrophy; Male; Middle Aged; Pruritus; Pyoderma Gangrenosum; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Scalp Dermatoses; Skin; Stavudine; Zalcitabine; Zidovudine | 2000 |
Assessment of developmental toxicity of antiretroviral drugs using a rat whole embryo culture system.
Topics: Abnormalities, Drug-Induced; Animals; Anti-HIV Agents; Crown-Rump Length; Didanosine; Drug Therapy, Combination; Embryo, Mammalian; Female; HIV Protease Inhibitors; Indinavir; Organ Culture Techniques; Pregnancy; Rats; Rats, Sprague-Dawley; Zalcitabine; Zidovudine | 2000 |
Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside-resistant human immunodeficiency virus type 1.
Topics: Amino Acid Sequence; Anti-HIV Agents; Didanosine; Drug Resistance; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Sequence Data; Mutagenesis, Site-Directed; Virus Replication; Zalcitabine; Zidovudine | 2000 |
A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215.
Topics: Anti-HIV Agents; Codon; Didanosine; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Genotype; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Nucleic Acid Hybridization; Point Mutation; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Zalcitabine; Zidovudine | 2000 |
Synergistic inhibition of HIV-1 in activated and resting peripheral blood mononuclear cells, monocyte-derived macrophages, and selected drug-resistant isolates with nucleoside analogues combined with a natural product, resveratrol.
Topics: Cell Division; Didanosine; Dose-Response Relationship, Drug; Drug Resistance; Drug Synergism; HIV-1; Humans; Hydroxyurea; Leukocytes, Mononuclear; Macrophages; Nucleosides; Resveratrol; Stilbenes; Virus Replication; Zalcitabine; Zidovudine | 2000 |
A bend in the road--implications of ACTG 175 and Delta trials.
Topics: Anti-HIV Agents; Australia; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Europe; HIV Infections; HIV-1; Humans; Survival Analysis; United States; Zalcitabine; Zidovudine | 1996 |
Anti-HIV therapy lowers risk of AIDS, death in patients with intermediate-stage HIV disease.
Topics: Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Survival Rate; Zalcitabine; Zidovudine | 1995 |
Crixivan reduces viral load.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Viral Load; Zalcitabine; Zidovudine | 1996 |
AZT studies reinforce benefits of combination.
Topics: Antiviral Agents; CD4-Positive T-Lymphocytes; Didanosine; Drug Synergism; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Lymphocyte Count; Zalcitabine; Zidovudine | 1995 |
Treatment briefs.
Topics: CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Industry; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Nerve Growth Factors; Nervous System Diseases; Pyridines; Recombinant Proteins; Stavudine; Zalcitabine; Zidovudine | 1995 |
What we know about anti-HIV drugs.
Topics: Antiviral Agents; Didanosine; DNA, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; RNA, Viral; Stavudine; Zalcitabine; Zidovudine | 1995 |
Combination treatment and single drugs: interview with Margaret Poscher, M.D. Interview by John S. James.
Topics: Acyclovir; Administration, Oral; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Ganciclovir; HIV Infections; Humans; Lamivudine; Stavudine; Zalcitabine; Zidovudine | 1995 |
Combination treatment and single drugs: interview with Margaret Poscher, M.D. Interview by John S. James.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Approval; Drug Combinations; Drug Therapy, Combination; Health Services Accessibility; Humans; Insurance, Health; Lamivudine; Managed Care Programs; United States; Zalcitabine; Zidovudine | 1995 |
Antiretroviral drug resistance.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; RNA, Viral; Stavudine; Viremia; Zalcitabine; Zidovudine | 1995 |
Update on clinical trials of combination therapies for HIV infection.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Child; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Hydroxyurea; Lamivudine; RNA-Directed DNA Polymerase; Stavudine; Zalcitabine; Zidovudine | 1995 |
Update on HIV protease inhibitors.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Design; Drug Therapy, Combination; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Isoquinolines; Phosphorylation; Pyridines; Quinolines; Ritonavir; Saquinavir; Substrate Specificity; Thiazoles; Valine; Zalcitabine; Zidovudine | 1995 |
Protease inhibitors and prevention of cross resistance.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Carbamates; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Isoquinolines; Lamivudine; Nelfinavir; Pyridines; Quinolines; Saquinavir; Sulfonamides; Zalcitabine; Zidovudine | 1995 |
AZT delta study: major European/Australian study finds combinations better than AZT alone.
Topics: Acquired Immunodeficiency Syndrome; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Humans; Zalcitabine; Zidovudine | 1995 |
ACTG 175 and Delta.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Evaluation Studies as Topic; Humans; Treatment Outcome; Zalcitabine; Zidovudine | 1995 |
Making sense of 175 and Delta.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Approval; Drug Resistance, Microbial; Drug Therapy, Combination; Evaluation Studies as Topic; Humans; Zalcitabine; Zidovudine | 1995 |
New trials reach same conclusion: two drugs are better than AZT alone.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Data Interpretation, Statistical; Didanosine; Drug Therapy, Combination; Humans; Treatment Outcome; Zalcitabine; Zidovudine | 1995 |
Study results at a glance.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Humans; Zalcitabine; Zidovudine | 1995 |
Closing the circle on HIV--or not.
Topics: Antiviral Agents; Biomarkers; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Interleukin-2; Nelfinavir; Prognosis; RNA, Viral; Zalcitabine; Zidovudine | 1995 |
FDA triple header. Food and Drug Administration.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; CD4 Lymphocyte Count; Child; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Protease Inhibitors; Humans; Isoquinolines; Lamivudine; Mutation; Quinolines; Salvage Therapy; Saquinavir; Stavudine; United States; United States Food and Drug Administration; Zalcitabine; Zidovudine | 1995 |
Combination therapy increases survival.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Stavudine; Zalcitabine; Zidovudine | 1995 |
To treat or not to treat--approaches to antiretroviral therapy. Interview by Anthony J. Japour.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Didanosine; Drug Therapy, Combination; HIV; Humans; Lamivudine; Practice Patterns, Physicians'; RNA, Viral; Zalcitabine; Zidovudine | 1996 |
Benefits of combination therapy confirmed.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Treatment Failure; Zalcitabine; Zidovudine | 1995 |
Merck protease inhibitor: more news from Retroviruses Conference.
Topics: CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Pyridines; Zalcitabine; Zidovudine | 1996 |
AZT, ddI, and ddC combinations at FDA advisory hearing. Food and Drug Administration.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Humans; Zalcitabine; Zidovudine | 1996 |
Europe out of step with the US.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Didanosine; Drug Costs; Europe; HIV Protease Inhibitors; Humans; Isoquinolines; Lamivudine; Quinolines; Ritonavir; Saquinavir; Thiazoles; United States; Valine; Zalcitabine; Zidovudine | 1996 |
ACTG 175: new insights into treating patients with intermediate-stage HIV disease.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Humans; Zalcitabine; Zidovudine | 1995 |
Back to the nukes.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Stavudine; Zalcitabine; Zidovudine | 1996 |
Update on other antivirals.
Topics: Adenine; Antiviral Agents; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Organophosphonates; Stavudine; Zalcitabine; Zidovudine | 1996 |
Nipping HIV in the bud.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Didanosine; DNA, Viral; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Isoquinolines; Lamivudine; Pyridines; Quinolines; Ritonavir; Saquinavir; Stavudine; Thiazoles; Valine; Virus Replication; Zalcitabine; Zidovudine | 1996 |
Top AIDS researchers' strategy for antiretroviral treatment.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Patient Compliance; Practice Guidelines as Topic; RNA, Viral; Stavudine; Zalcitabine; Zidovudine | 1996 |
3TC: combination trial stopped early as clinical benefit shown.
Topics: Antiviral Agents; Clinical Trials as Topic; Didanosine; Disease Progression; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Placebos; Treatment Failure; Zalcitabine; Zidovudine | 1996 |
Outdated yet out-of-reach: AIDS society treatment guidelines at the International Conference.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Antiviral Agents; CD4 Lymphocyte Count; Decision Making; Didanosine; Drug Therapy, Combination; HIV; HIV Infections; Humans; Lamivudine; Practice Guidelines as Topic; Zalcitabine; Zidovudine | 1996 |
ddI and d4T plus protease inhibitors.
Topics: Anti-HIV Agents; Didanosine; HIV Infections; Humans; Lamivudine; Stavudine; Zalcitabine; Zidovudine | 1996 |
NIAID researchers present new findings at retrovirus meeting. National Institute of Allergy and Infectious Diseases.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Chemokines; Clinical Trials as Topic; Clone Cells; Dendritic Cells; Didanosine; Disease Progression; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Interleukin-10; Killer Cells, Natural; Lamivudine; Male; Nevirapine; Pyridines; Receptors, Cytokine; Reverse Transcriptase Inhibitors; Ritonavir; Virus Replication; Zalcitabine; Zidovudine | 1997 |
Update on nevirapine: quest for a niche.
Topics: Adult; Anti-HIV Agents; Child; Clinical Trials as Topic; Didanosine; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Infant, Newborn; Nevirapine; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1997 |
Hydroxyurea, a potential new anti-HIV agent.
Topics: Didanosine; DNA Replication; Drug Therapy, Combination; HIV; HIV Infections; Humans; Hydroxyurea; Leukocytes, Mononuclear; Virus Replication; Zalcitabine; Zidovudine | 1995 |
Antiretroviral therapy for adults and children.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child; Didanosine; Female; HIV Infections; Humans; Pregnancy; Pregnancy Complications, Infectious; Primary Health Care; Stavudine; Viral Load; Zalcitabine; Zidovudine | 1995 |
Differential susceptibility of retroviruses to nucleoside analogues.
Topics: Animals; Antiviral Agents; Cell Line; Cricetinae; Didanosine; Dose-Response Relationship, Drug; Humans; Inhibitory Concentration 50; Lamivudine; Mink; Nucleosides; Retroviridae; Reverse Transcriptase Inhibitors; Stavudine; Substrate Specificity; Zalcitabine; Zidovudine | 2001 |
Differential effects of nucleoside analogs on oxidative phosphorylation in human pancreatic cells.
Topics: Antimetabolites; Cells, Cultured; Didanosine; Dideoxyadenosine; DNA, Mitochondrial; Humans; Oxidative Phosphorylation; Pancreas; Zalcitabine | 2001 |
Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons.
Topics: Anti-HIV Agents; Base Sequence; Didanosine; Dideoxynucleosides; DNA, Viral; Drug Resistance, Viral; Evolution, Molecular; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Sequence Data; Mutagenesis; Recombination, Genetic; Reverse Transcriptase Inhibitors; Stavudine; Virus Replication; Zalcitabine; Zidovudine | 2001 |
Viral and immunologic follow up of 4 to 9 years of AIDS treatments by quadruple combinations of virostatics including integrase inhibitors applied in short sequences differing by drug rotation.
Topics: Acquired Immunodeficiency Syndrome; Acriflavine; Adult; Anti-HIV Agents; Antiviral Agents; CD4-CD8 Ratio; Didanosine; Drug Therapy, Combination; Ellipticines; Female; Follow-Up Studies; HIV-1; Humans; Integrase Inhibitors; Male; Middle Aged; Protease Inhibitors; Stavudine; Vitamin B 12; Zalcitabine; Zidovudine | 2002 |
Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors.
Topics: Adenine; Anti-HIV Agents; Antigens, CD34; Cell Line; Didanosine; Dideoxynucleosides; Epithelial Cells; Hematopoietic Stem Cells; Humans; Kidney Tubules, Proximal; Liver; Muscle, Skeletal; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Tumor Cells, Cultured; Zalcitabine; Zidovudine | 2002 |
The dangers of inferring treatment effects from observational data: a case study in HIV infection.
Topics: Adult; Anti-HIV Agents; Data Interpretation, Statistical; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Observation; Randomized Controlled Trials as Topic; Selection Bias; Zalcitabine; Zidovudine | 2002 |
An ancient prevertebrate Na+-nucleoside cotransporter (hfCNT) from the Pacific hagfish (Eptatretus stouti).
Topics: Amino Acid Sequence; Animals; Anti-HIV Agents; Chimera; Cloning, Molecular; Didanosine; DNA, Complementary; Hagfishes; Kinetics; Molecular Sequence Data; Oocytes; Protein Isoforms; Recombinant Proteins; Symporters; Xenopus; Zalcitabine; Zidovudine | 2002 |
Human immunodeficiency virus 1 strains resistant to nucleoside inhibitors of reverse transcriptase in isolates from the Czech Republic as monitored by line probe assay and nucleotide sequencing.
Topics: Base Sequence; Codon; Czech Republic; Didanosine; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Molecular Probe Techniques; Molecular Sequence Data; Mutation; Phylogeny; Prevalence; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA; Zalcitabine; Zidovudine | 2001 |
[Mononucleosis syndrome with viro-immunologic parameters similar to those of a primary HIV-1 infection after interruption of highly effective anti-retroviral treatment].
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; Depression; Didanosine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infectious Mononucleosis; Male; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Treatment Refusal; Trimethoprim, Sulfamethoxazole Drug Combination; Viral Load; Viremia; Zalcitabine; Zidovudine | 2002 |
Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information.
Topics: Adenine; Anti-HIV Agents; Carbamates; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Microbial Sensitivity Tests; Organophosphonates; Organophosphorus Compounds; Phenotype; Reverse Transcriptase Inhibitors; Sulfonamides; Tenofovir; Zalcitabine | 2002 |
HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).
Topics: Adenine; Anti-HIV Agents; Cell Line; Cytidine Triphosphate; Didanosine; Drug Resistance, Multiple, Viral; Genotype; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Species Specificity; Tenofovir; Transfection; Zalcitabine; Zidovudine | 2003 |
Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine+didanosine or zidovudine+zalcitabine) vs. single (zidovudine) nucleoside reverse transcriptase inhibitors.
Topics: Analysis of Variance; Anti-HIV Agents; Didanosine; DNA, Mitochondrial; Drug Combinations; HIV Infections; Humans; Mitochondrial Diseases; Reverse Transcriptase Inhibitors; Self-Sustained Sequence Replication; Sensitivity and Specificity; Zalcitabine; Zidovudine | 2004 |
Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine.
Topics: Acidosis, Lactic; Adult; Cross-Sectional Studies; Didanosine; DNA, Mitochondrial; Female; Hepatitis C, Chronic; HIV Infections; Humans; Lactic Acid; Liver; Male; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine | 2004 |
Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance.
Topics: Adenine; Algorithms; Anti-HIV Agents; Databases, Genetic; Didanosine; Dideoxynucleosides; Drug Resistance, Multiple, Viral; HIV; HIV Infections; Humans; Mutation; Organophosphonates; Organophosphorus Compounds; Phenotype; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Thymidine; Zalcitabine; Zidovudine | 2004 |
Gene repair in mammalian cells is stimulated by the elongation of S phase and transient stalling of replication forks.
Topics: Amino Acid Sequence; Animals; Base Sequence; Cell Line; Didanosine; DNA Repair; DNA Replication; Flow Cytometry; Genes, Reporter; Green Fluorescent Proteins; Peptide Chain Elongation, Translational; Point Mutation; S Phase; Zalcitabine | 2005 |
Mitochondrial toxicity of nucleoside analogues in primary human lymphocytes.
Topics: CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cells, Cultured; Didanosine; DNA, Mitochondrial; Female; Humans; Lactic Acid; Lymphocyte Activation; Male; Mitochondrial Diseases; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine | 2005 |
Simple adjustments for randomized trials with nonrandomly missing or censored outcomes arising from informative covariates.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Humans; Likelihood Functions; Longitudinal Studies; Models, Statistical; Nevirapine; Proportional Hazards Models; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Zalcitabine; Zidovudine | 2006 |
Real-time nucleic acid sequence-based amplification assay to quantify changes in mitochondrial DNA concentrations in cell cultures and blood cells from HIV-infected patients receiving antiviral therapy.
Topics: Anti-HIV Agents; Base Sequence; Blood Platelets; Cell Nucleus; Cells, Cultured; Didanosine; DNA, Mitochondrial; Drug Therapy, Combination; Feasibility Studies; Fibroblasts; HIV Infections; Humans; Indinavir; Lactic Acid; Lamivudine; Leukocytes, Mononuclear; Nucleic Acid Amplification Techniques; Pyruvic Acid; Stavudine; Zalcitabine | 2006 |
The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations.
Topics: Adenine; Amino Acid Substitution; Anti-HIV Agents; Arginine; Didanosine; Dideoxynucleosides; Drug Resistance, Multiple, Viral; Genotype; HIV Reverse Transcriptase; HIV-1; Humans; Lysine; Organophosphonates; Phenotype; Point Mutation; Reverse Transcriptase Inhibitors; Tenofovir; Thymidine; Zalcitabine; Zidovudine | 2006 |
Distal sensory polyneuropathy in HIV-positive patients in the HAART era: an entity underestimated by clinical examination.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Electrophysiology; Female; HIV Infections; Humans; Male; Middle Aged; Polyneuropathies; Prevalence; Reverse Transcriptase Inhibitors; Risk Factors; Stavudine; Zalcitabine | 2006 |
Semiparametric analysis of recurrent events: artificial censoring, truncation, pairwise estimation and inference.
Topics: AIDS-Related Opportunistic Infections; Computer Simulation; Data Interpretation, Statistical; Didanosine; HIV Infections; Humans; Kaplan-Meier Estimate; Models, Statistical; Recurrence; Zalcitabine | 2010 |
p53 and mitochondrial DNA: their role in mitochondrial homeostasis and toxicity of antiretrovirals.
Topics: Cell Proliferation; Didanosine; DNA Replication; DNA, Mitochondrial; Hep G2 Cells; Homeostasis; Humans; Mitochondria; Reverse Transcriptase Inhibitors; Transfection; Tumor Suppressor Protein p53; Zalcitabine | 2012 |
Anti-HIV efficacy and biodistribution of nucleoside reverse transcriptase inhibitors delivered as squalenoylated prodrug nanoassemblies.
Topics: Adenosine Triphosphate; Animals; Anti-HIV Agents; Didanosine; Drug Resistance, Viral; Light; Nanoparticles; Nucleosides; Particle Size; Prodrugs; Rats; Rats, Wistar; Reverse Transcriptase Inhibitors; Scattering, Radiation; Squalene; Tissue Distribution; Treatment Outcome; Tritium; Zalcitabine | 2013 |
Caenorhabditis elegans as a Model System for Studying Drug Induced Mitochondrial Toxicity.
Topics: Animals; Anti-HIV Agents; Caenorhabditis elegans; Didanosine; Dideoxynucleosides; DNA-Directed DNA Polymerase; DNA, Mitochondrial; Drug Evaluation; Humans; Mitochondria; Mitochondrial Proteins; Models, Biological; Oxygen Consumption; Reverse Transcriptase Inhibitors; Stavudine; Ubiquinone; Zalcitabine; Zidovudine | 2015 |
Structural Insights into HIV Reverse Transcriptase Mutations Q151M and Q151M Complex That Confer Multinucleoside Drug Resistance.
Topics: Anti-HIV Agents; Crystallography, X-Ray; Didanosine; DNA-Binding Proteins; Drug Resistance, Viral; Gene Products, pol; Hepatitis B virus; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Protein Conformation; Protein Structure, Quaternary; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 2017 |
A Lower Baseline CD4/CD8 T-Cell Ratio Is Independently Associated with Immunodiscordant Response to Antiretroviral Therapy in HIV-Infected Subjects.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; CD4-CD8 Ratio; CD8-Positive T-Lymphocytes; Cell Survival; Didanosine; Female; HIV Infections; Humans; Male; Middle Aged; Receptors, CXCR4; Stavudine; T-Lymphocytes, Regulatory; Viral Load; Zalcitabine; Zidovudine | 2017 |
Sustainable Protocol for the Synthesis of 2',3'-Dideoxynucleoside and 2',3'-Didehydro-2',3'-dideoxynucleoside Derivatives.
Topics: Anti-HIV Agents; Didanosine; Dideoxynucleosides; Stavudine; Zalcitabine; Zidovudine | 2022 |